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Abstract
The advantage of using meta-analysis lies in its ability in providing a quantitative
summary of the findings from multiple studies. The aim of this dissertation was first to
conduct a simulation study in order to understand what factors (sample size, betweenstudy correlation, and percent of missing data) have a significant effect on meta-analysis
estimates and whether using univariate or multivariate meta-analysis would produce
different estimates.
The second goal of this study was to evaluate the effect of clinical decision
support systems CDSS on diabetes care management by conducting three separate
univariate meta-analyses and one multivariate meta-analysis. CDSS are health
information technology systems that analyze data within electronic health records (EHR)
to help make decisions about a patient's care. Several studies reported inconsistent
conclusions about how effective CDSSs are on diabetes care management based on three
indicators. Low-density lipoproteins (LDL), glycated hemoglobin (HbA1c), and blood
pressure (PB) have been used as indicators of diabetes care management according to the
National Institute for Health and Care Excellence (NICE) guidelines. To combine the
results from studies that evaluate the effect of CDSSs on diabetes care management,
meta-analysis was used. The results of the two univariate and multivariate meta-analyses
were compared.
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The simulation study indicated that MVMA was less affected by missing values
compared to UVMA. However, both methods performed equally when no missing data
were present. The standard errors of the estimates in both methods were reduced by
increasing the sample size with more reduction in standard errors found in MVMA. The
results of UVMA and MVMAs of CDSSs’ effect concluded that CDSSs had a significant
effect on reducing levels of HbA1c. CDSSs was only significant on LDL when UVMA
was applied while pulse pressure (PP) was only affected by CDSSs in the case of MVMA
with deleted missing values. CDSSs in general could have a potential effect on diabetes
care management.
The results of the simulation and the meta-analyses of the CDSSs indicated that
MVMA performed slightly better at different sample sizes and percent of missingness
levels than did UVMA.
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Chapter One
Introduction and Literature Review
Findings from a single study generally need to be replicated by independent
studies for the research and practitioner communities to treat the findings as accurate. It
would be unusual for important decisions to be made about, for example, treatment
efficacy, based on results of one single study. An analytical approach that integrates the
results of independent studies and pools their results into a single typical result is needed.
In 1976, Gene Glass referred to the statistical analysis of an extensive collection of
results from independent studies for the purpose of integrating the findings as “metaanalysis” (O’Rourke, 2007). While systematic literature reviews provide a framework for
the combination of studies, meta-analysis provides a quantitative summary of the findings
from multiple studies. In this study, I compared estimates produced by conducting
multiple univariate meta-analyses (UVMA) with estimates from multivariate metaanalyses (MVMA) which take into account multiple outcomes simultaneously. This
comparison was done using simulation and an empirical comparison using real data from
an applied context. In the simulation study, I show under what conditions the utilization
of MVMA is optimal and then an empirical comparison between MVMA and UVMA
using real data of clinical decision support systems (CDSS) and their effects on diabetes
care management follows. There are multiple issues that might affect differences between
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MVMA and UVMA. They include between and within study correlation, number
of studies included (sample size), and the percent of missing data. Several studies that
compared estimates of the UVMA and MVMA reported almost identical results. For
instance, Schwarzer et al. (2015) examined the results of univariate and MVMA using a
non-random sample of five studies of a systematic review and meta-analysis study done
by Lloyd et al. (2010). The result of this comparison yielded almost identical estimates
when the within-study correlation was zero and differed by within only one standard
error (and so differences were nonsignificant) as the correlation moved from 0.9 to -0.9.
Another study by Trikalinos et al. (2014) found that conclusions based on the main
effects of each outcome were similar to either univariate or multivariate meta-analysis.
So, while the within-study correlation would seem important, no support for its effects on
outcomes has been found.
Another problem that might affect meta-analysis results is when there are missing
outcome data. Missing data present a threat to the validity of any meta-analysis of
research studies. In any analysis, it is assumed that the data are missing completely at
random (MCAR) or missing at random (MAR). However, if the data are analyzed as if
they were MCAR or MAR but in fact are not MAR, then bias typically occurs (Ellington
et al., 2015). Missing data is a common issue in meta-analysis. For instance, in the case
of UVMA, studies that do not have all outcomes of interest will be excluded from the
study and that might be costly in terms of losing information. However, that is not the
case in MVMA. Having only one outcome is enough for a study to be included.
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Determining how missingness would affect the quality of UVMA and MVMA estimates
is vital and this study was designed to assess effects of the amount of missing data.
In this study, the researcher explored under what conditions the estimates of a
MVMA are similar to estimates from UVMA. The researcher explored effects of
between-study correlation, percentage of missing data, and sample size through a
simulation study followed by an empirical comparison of UVMA and MVMA using
studies of CDSSs.
The evaluation of the impact of CDSSs in improving the quality of diabetes care
was another interest in this study and was the context for an empirical comparison of
UVMA and MVMA. A CDSS is “any electronic system designed to aid directly in
clinical decision making, in which characteristics of individual patients are used to
generate patient-specific assessments or recommendations that are then presented to
clinicians for consideration” (Kawamoto et al., 2005). Several indicators were used as a
guide in assessing the quality of care. Those indicators were: low-density lipid
cholesterol (LDL-C), glycated hemoglobin (HbA1c), and blood pressure (BP). It has been
shown that the simultaneous control of HbA1c, BP, and LDL-C reduces the risk of
diabetes complications and death (Hu et al., 2016a). The indicators that the researcher
used as a guide follow the National Institute for Health and Care Excellence (NICE)
guidelines.
Research Questions and Hypotheses
This study was designed to answer six research questions and seven hypotheses.
One question was answered using a simulation. The other questions and their associated
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hypotheses were answered by conducting UVMA and MVMA. Hypotheses are stated in
alternative form.
Simulation study research questions and hypotheses
Q1. Are there differences in parameter estimates when method (UVMA/MVMA), sample
size, between-study correlation, and the percentage of missingness are varied?
𝐻1 : There are interpretable main effects (Partial eta squared 𝜂𝑝2 ≥ 0.01) of sample
size, between-study correlation, and the percentage of missingness on the parameter
estimates (effect size, standard error).
𝐻2 : There are interpretable interactions (Partial eta squared 𝜂𝑝2 ≥ 0.01) among
sample size, between-study correlation, and the percentage of missingness.
𝐻3 : There is an interpretable main effect (Partial eta squared 𝜂𝑝2 ≥ 0.01) of
method (UVMA/MVMA) on parameter estimates.
UVMA research questions and hypotheses
Q2. What are the effects of CDSSs in controlling HbA1c levels among diabetic patients?
𝐻4 : CDSSs have a significant effect in controlling HbA1c levels for diabetic
patients.
Q3. What are the effects of CDSSs in controlling BP levels for diabetic patients?
𝐻5 : CDSSs have a significant effect in controlling BP levels among diabetic
patients.
Q4. What are the effects of CDSSs in controlling LDL-C levels among diabetic patients?
𝐻6 : CDSSs have a significant effect in controlling LDL-C levels for diabetic
patients.
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MVMA research question and hypotheses
Q5. What are the effects of CDSSs on simultaneous control of HbA1c, BP, and LDL-C
among diabetic patients?
𝐻7 : CDSSs have a significant effect on simultaneous control of HbA1c, BP, and
LDL-C among diabetic patients.
UVMA and MVMA comparison research question
Q6. Is there a difference in the estimates between multivariate meta-analysis and
univariate meta-analysis of CDSSs?
This study is organized as follows. In the following section, the MVMA model
and its applications are reviewed, with emphasis on studies that have used both MVMA
and UVMA. UVMA and MVMA computation and fitting techniques are then addressed
and followed by a conceptual comparison. Then, issues related to and limitations of
MVMA are discussed. Finally, a summary of studies that evaluated the effect of the
CDSSs in improving diabetes care are presented.
Review of the Literature
Meta-analysis has been promoted for over 30 years, with applications in
education, dentistry, clinical trials, survival, marketing, surrogate outcomes, prognostic
markers, diagnostic tests, and genetics among others. According to Jackson et al. (2011),
the most common areas where the application of meta-analysis has been particularly
successful are: (a) diagnostic test meta-analysis; (b) multiple effects in randomized
controlled trials or observational studies; (c) multiple parameter models for exposure in
observational studies; and (d) network meta-analysis. The bivariate meta-analysis of
studies of diagnostic test quality is probably the most common medical application of
5

meta-analysis. In the case of multiple effects and in any situation where clinical trials or
observational studies have more than one outcome of interest, an MVMA could be
applied. In the third case listed above (c), the aim is to pool information across studies for
exposure parameters that characterize effects of specific interest. In network analysis,
multiple treatments are compared across studies that provide results for multiple
treatment groups. UVMA dominates meta-analysis studies to date, though many research
projects deliberately include multiple outcome measures which would make MVMA
seem the obvious analytic choice.
Multiple approaches are available to compute multivariate effect sizes. Averaging
the multivariate effect sizes within each study is one of them. It is adequate to apply
univariate meta-analysis since averaged effect sizes are independent across studies.
However, averaging is usually not suitable when the multivariate effect sizes are
measuring non-combinable different constructs such as academic achievement and
student engagement. Another approach is to meta-analyze each effect size separately.
This approach is relatively easy to implement. However, the dependence among the
effect sizes is ignored as is any differences in between-study dependencies. A third
approach is modeling the multivariate effect sizes simultaneously where the dependency
among the effect sizes is taken into account. This is usually more appropriate than
conducting separate univariate meta-analyses since MVMA employs the correlation
among the multivariate effect sizes (Cheung, 2013).
Univariate Meta-Analysis Effect Size Computation
In meta-analysis, an important step is computation of the effect size. Effect sizes
should be carefully computed since they represent essential information that will be
6

extracted from the studies included. Pearson correlation coefficients (r), standardized
mean differences (g), and odds ratios (OR) are common indices that represent effect
sizes. It should be noted that significance tests are not effect sizes and vice versa (Card,
2015). In general, there are two models in meta-analysis, fixed-effects models and
random-effects models, with mixed-effects models reflecting a mixture of fixed- and
random-effects models. In the case of the fixed-effects models, it is assumed that the
population effect sizes are the same across studies. However, in random-effects models,
each study assumed to have its own effect sizes. Fixed-effects models are suitable if the
researcher has included in the meta-analysis all (or mostly all) studies that are available
for population of interest. In this case, the interest is to draw conclusions from the
included studies. If the researcher intends to generalize findings, random- or mixedeffects models are more suitable. Next, the three indices of effect sizes are described, and
their formulas presented before the advantages and disadvantages of applying MVMA are
reviewed.
Pearson Correlation (r)
The Pearson correlation coefficient represents the association between two
continuous variables and the formula used for the computation of r is:
𝑟=

∑(𝑥𝑖 −𝑥̅ )(𝑦𝑖 −𝑦̅)
(𝑁−1)𝑠𝑥 𝑠𝑦

=

∑ 𝑍𝑋 𝑍𝑌
𝑁

where
𝑥𝑖 and 𝑦𝑖 are the values of individual i on the two variables
𝑥̅ and 𝑦̅ are the sample means of the two variables.
𝑁 is the sample size
7

Eq. 1

𝑠𝑥 and 𝑠𝑦 represent the population estimated standard deviations of the two variables.
𝑍𝑋 =

𝑥𝑖 −𝑥̅
𝑠𝑥

and 𝑍𝑌 =

𝑦𝑖 −𝑦̅
𝑠𝑦

are the standardized scores.

A Correlation ρ itself is directly taken as an effect size. Even though Pearson’s r is
considered as an interpretable index of effect size for the association between two
continuous variables, r is transformed prior comparing effect sizes across studies. One of
the most common transformation is Fisher’s transformation (𝑍𝑟 ) as shown below in Eq.
2.
1

1+𝑟)

Eq. 2

𝑍𝑟 = 2 𝑙𝑛 ( 1−𝑟 )
And the standard error of 𝑍𝑟 is
𝑆𝐸𝑍𝑟 =

1
√𝑁−3

Eq. 3

where
𝑍𝑟 represents Fisher’s transformation of r.
r is Pearson’s correlation coefficient.
N is the sample size of the study.
The reason behind transforming r to 𝑍𝑟 is that the distribution of r around a given
nonzero population 𝜌 is skewed, especially when the sample size is not large enough,
whereas the distribution of 𝑍𝑟 around a nonzero population ρ is symmetric (Card, 2015).
Standardized Mean Difference (g)
The standardized mean difference represents “the magnitude of difference
between the means of two groups as a function of the group’s standard deviation” (Card,
2015). According to Card 2015, there are three common indices of standardized mean

8

difference. These indices are Hodges’s (g), Cohen’s (d), and Glass’s index (𝑔𝐺𝑙𝑎𝑠𝑠 ). The
equations below represent the three indices respectively.
𝑔=

𝑀1 − 𝑀2
𝑆𝑝𝑜𝑜𝑙𝑒𝑑

Eq. 4,

𝑑=

𝑀1 − 𝑀2
𝑆𝑑𝑝𝑜𝑜𝑙𝑒𝑑

Eq. 5,

𝑔𝐺𝑙𝑎𝑠𝑠 =

𝑀1 − 𝑀2
𝑆1

Eq. 6

where
𝑀1 and 𝑀2 are the means of the two groups.
( 𝑥𝑖 −𝑥̅ )2

𝑆𝑝𝑜𝑜𝑙𝑒𝑑 = √

(𝑛−1)

represents the pooled estimates of the population standard deviation.

( 𝑥𝑖 −𝑥̅ )2

𝑆𝑑𝑝𝑜𝑜𝑙𝑒𝑑 = √

𝑛

is the pooled sample standard deviation.

𝑆1 is the estimate of the population standard deviation from the control group.
The standard error of g is given below
𝑛 +𝑛

𝑔2

𝑆𝐸𝑔 = √ 𝑛1 𝑛 2 + 2(𝑛
1 2

1 +𝑛2

4𝑔2

≈𝑁
)

𝑡𝑜𝑡𝑎𝑙

Eq. 7

where
𝑛1 and 𝑛2 represent the sample sizes of group 1 and group 2.
𝑁𝑡𝑜𝑡𝑎𝑙 is the total sample size of the study assuming equal sample size per group.
Correction is needed when the primary study sample size is small. The
standardized mean difference has been shown to be a biased estimate when the sample
sizes are small (less than 20). Therefore, the following adjustment should be applied for
small sample size (French et al., n.d.):
𝑔𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 = 𝑔 − 4(𝑛

3𝑔

1 +𝑛2 )−9

9

Eq. 8

Odds Ratio (OR)
Another useful index of effect size of the association between two dichotomous
variables is the odds ratio (OR). OR is defined as the probability of the event divided by
the probability of the alternative (Card, 2015). The0 OR can be calculated from a 2 × 2
table using the following formula:
𝐸𝑆𝑂𝑅 =

𝑎𝑑
𝑏𝑐

=

𝑃𝑎 𝑃𝑑
𝑃𝑏 𝑃𝑐

=

𝑃𝑎
⁄𝑃
𝑏
𝑃𝑐
⁄𝑃
𝑑

𝑃 (1−𝑃 )

= 𝑃𝑎(1−𝑃𝑐
𝑐

𝑎)

Eq. 9

where a, b, c, and d represent the cell frequencies and 𝑃𝑎 , 𝑃𝑏 𝑃𝑐 , and 𝑃𝑑 are the proportion
of each group in each status.
In meta-analysis, the natural log of the OR is used, which has an approximately
normal distribution with a mean of 0 and a standard deviation of 1.83 (Lipsey & Wilson,
2001). By using the logged odds, the interpretation of the effect size becomes clearer and
makes the calculation of the standard error easier. The logged OR, standard error, and
inverse variance weight can be calculated as the following:
𝐸𝑆𝐿𝑂𝑅 = 𝐿𝑜𝑔(𝐸𝑆𝑂𝑅 )
1

1

1

1

Eq. 11

= 𝑎𝑏(𝑐+𝑑)+𝑐𝑑(𝑎+𝑏)

Eq. 12

𝑆𝐸𝐿𝑂𝑅 = √𝑎 + 𝑏 + 𝑐 + 𝑑
𝑤𝐿𝑂𝑅 = 𝑆𝐸

1

𝐿𝑂𝑅

Eq. 10

𝑎𝑏𝑐𝑑

Multivariate Meta-Analysis Effect Size Computation
I start with the model of bivariate meta-analysis and then extend it to MVMA
model for simplicity. Therefore assume 𝑗 = 1,2 so that each study 𝑖 yields two estimated
treatment effects: 𝑦𝑖 = (𝑦𝑖1 , 𝑦𝑖2 )′ . In the fixed effects case, the study estimates will
follow a bivariate normal distribution (Mavridis & Salanti, 2013).
10

𝑦𝑖1
𝜇1
(𝑦 ) ~𝐵𝑁𝐷 ((𝜇 ) , (
𝑖2

2

2
𝜎𝑖1
𝜌𝑖 𝜎𝑖1 𝜎𝑖2

𝜌𝑖 𝜎𝑖1 𝜎𝑖2
))
2
𝜎𝑖2

Eq. 13

where 𝜌𝑖 represents the within-study correlation between outcomes 𝑗 = 1,2 for study 𝑖.
The vector (𝜇1 , 𝜇2 )′ is the vector of means for each outcome. The matrix 𝑆𝑖 =
2
𝜎𝑖1
(
𝜌𝑖 𝜎𝑖1 𝜎𝑖2

𝜌𝑖 𝜎𝑖1 𝜎𝑖2
) represents the within-study covariance matrix. The overall
2
𝜎𝑖2

correlation in the two-dimensional case is split into two components, within-study
correlation (𝜌𝑖 ) and between-study correlation (𝜌𝜏 ) where:
2
𝑦𝑖1
𝜎𝑖1
𝜃𝑖1
𝜃𝑖1
(𝑦 ) |( ) ~𝐵𝑁𝐷 (( ) , (
𝜃𝑖2
𝜃𝑖2
𝑖2
𝜌𝑖 𝜎𝑖1 𝜎𝑖2

The vector 𝜃 = (𝜃𝑖1

𝜌𝑖 𝜎𝑖1 𝜎𝑖2
))
2
𝜎𝑖2

Eq. 14

𝜃𝑖2 )′ is the study-specific effects for each outcome. 𝜃 is also

normally distributed.
𝜇1
𝜃
𝜏2
( 𝑖1 ) ~𝐵𝑁𝐷 ((𝜇 ) , ( 1
𝜃𝑖2
2
𝜌𝜏 𝜏1 𝜏2

𝜌𝜏 𝜏1 𝜏2
))
𝜏22

Eq. 15

where 𝜏𝑗 is defined as the between-study variation (heterogeneity) for effect size 𝑗.
When jointly meta-analyzed the outcomes, in addition to the matrix 𝑆𝑖 , there is also a
between-study covariance matrix, ∆= (

𝜏12
𝜌𝜏 𝜏1 𝜏2

𝜌𝜏 𝜏1 𝜏2
). By combining Eq. 14 and Eq.
𝜏22

15 we get
𝑦𝑖1
𝜇1
(𝑦 ) ~𝐵𝑁𝐷 ((𝜇 ) , (
𝑖2

2

2
𝜎𝑖1
+ 𝜏12
𝜌𝑖 𝜎𝑖1 𝜎𝑖2 + 𝜌𝜏 𝜏1 𝜏2

𝜌𝑖 𝜎𝑖1 𝜎𝑖2 + 𝜌𝜏 𝜏1 𝜏2
))
2
𝜎𝑖1
+ 𝜏22

Eq. 16

Eq. 16 can be extended for the case of 𝑝 outcomes as follows
2
𝑦𝑖1
𝜇1
𝜎𝑖1
+ 𝜏12
( ⋮ ) ~𝑀𝑁𝐷 (( ⋮ ) , (
⋮
𝑦𝑖𝑝
𝜇𝑝
𝜌𝑖 𝜎𝑖1 𝜎𝑖𝑝 + 𝜌𝜏(1,𝑝) 𝜏1 𝜏𝑝
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…
⋱
…

𝜌𝑖 𝜎𝑖1 𝜎𝑖𝑝 + 𝜌𝜏(1,𝑝) 𝜏1 𝜏𝑝
)) Eq. 17
⋮
2
2
𝜎𝑖𝑝 + 𝜏𝑝

The following equation is the matrix representation of the random-effects model
𝒚 𝒊 = 𝝁 + 𝜹𝒊 + 𝜺 𝒊

Eq. 18

𝑤ℎ𝑒𝑟𝑒 𝜹𝑖 is a vector of random effects of the study 𝑖 where 𝜹𝒊 ~𝑀𝑉𝑁(0, ∆)and 𝜀𝑖
represents a vector of random sampling error of the study 𝑖. 𝜺𝒊 is independent of 𝜹𝒊 and it
is normally distributed 𝜺𝒊 ~𝑀𝑉𝑁(0, 𝑆𝑖 ). The matrix ∆ is the between-study covariance as
defined previously but in this case, it is involving two unknown parameters 𝜏𝑗 and 𝜌𝜏(𝑗𝑗′ )
𝜏12
∆= (
⋮
𝜌𝜏(1,𝑝) 𝜏1 𝜏𝑝

… 𝜌𝜏(1,𝑝) 𝜏1 𝜏𝑝
)
⋱
⋮
2
…
𝜏𝑝

Eq. 19

the variance–covariance matrix of 𝑦𝑖 is ∆ + 𝑆𝑖 and by including 𝑙 covariates in the model
in Eq. 17 so that:

𝜇 = 𝑋𝑖 𝛽𝑦𝑖 = 𝑋𝑖 𝛽 + 𝛿𝑖 + 𝜀𝑖

Eq. 20
The previous equation is the general random-effects multiple outcomes metaregression model which is also known as a mixed effects model. 𝑋𝑖 represents the
𝑝 × (𝑙 + 1) the observed covariate values matrix for each study and 𝛽 is the vector of 𝑙
coefficients and the constant term.
Fitting multivariate meta-analysis models
There are several approaches in order to estimate the MVMA model parameters.
In the MVMA model, the parameters of interest are 𝝁, the vector of the effect estimates
for the 𝒑 outcomes, 𝒑 × 𝒑 variance–covariance matrix 𝑪, and the heterogeneities 𝝉𝟐𝒋 and
between-studies correlations 𝝆𝝉 represented by the matrix ∆. In this section, I summarize
several estimation methods in the case of the random-effects model since the fixed effects
estimates computations are simpler and are considered as a special case.
12

Likelihood methods
To estimate model parameters, likelihood methods can be used with the
assumption of the independence of the studies. The likelihood is defined as:
1

1

𝐿 ≈ − 2 ∑𝑛𝑖=1 𝑙𝑜𝑔|∆ + 𝑆𝑖 | − − 2 ∑𝑛𝑖=1 𝑒𝑖′ (∆ + 𝑆𝑖 )−1 𝑒𝑖

Eq.21

The only disadvantage of the likelihood methods is that when the number of
studies is large, they become computationally intensive and time consuming.
Maximum likelihood (ML) estimates
With the assumption that all studies have the same outcomes and there are no
missing values, the effect estimates could be estimated by maximizing the likelihood as
follows:
−1

−1
𝜇̂ = (∑𝑛𝑖=1(∆̂ + 𝑆𝑖 ) ∑𝑛𝑖=1(∆̂ + 𝑆𝑖 ))

𝑦

Eq.22
The estimates produced by Eq.22 are approximately normally distributed with variance
covariance matrix:
−1

−1
𝐶̂ = (∑𝑛𝑖=1(∆̂ + 𝑆𝑖 ) )

Eq.23
Restricted ML (REML)
This estimation approach is very common in the literature since it produces
unbiased estimates of variance and covariance parameters. The REML is defined as:
−1

1

𝑅𝐿 ≈ − 2 |∑𝑛𝑖=1(∆̂ + 𝑆𝑖 ) |
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Eq.24

By maximizing the likelihood functions, positive definiteness will be ensured in ∆.
Estimates of 𝜇 and 𝐶 could be obtained by using the estimated ∆̂ in equations (22) and
(23).
Generalized least squares (GLS)
In this method, it is assumed that each outcome could be modelled by a regression
line and regression models are not independent and therefore, correlations are considered.
The matrix X when there are no covariates in the model is defined as:
𝑋1
𝑋=[ ⋮ ]
𝑋𝑛
where 𝑋𝑖 is the identity 𝑝 × 𝑝 matrix. GLS could be maximized by
(𝑦 − 𝑋𝜇)′ 𝑆 −1 (𝑦 − 𝑋𝜇)

Eq.25

In the case of the fixed effects, the GLS estimates could be obtained as the follows:
𝜇̂ = (𝑋 ′ 𝑆 −1 𝑋)−1 𝑋 ′ 𝑆 −1 𝑦

Eq.26

The variance-covariance matrix is 𝐶̂ = (𝑋 ′ 𝑆 −1 𝑋)−1. The random effects estimator
estimates 𝜇̂ iteratively until a successful convergent is gained, and ∆̂=

1
1
(𝑛−2)𝑒 ′ 𝑒−
𝑛

∑𝑛
𝑖=1 𝑆𝑖

where 𝑒 = 𝑦 − 𝜇̂ .
In reviewing the effect size computation formulas for UVMA and MVMA,
differences appear in how both approaches are constructed. MVMA uses matrix notation
since more than one outcome variable is included in a simultaneous analysis while only
one outcome is handled in the UVMAs. A primary difference between UVMA and
MVMA is that in UVMA, outcomes are analyzed separately assuming that they are
independent. In MVMA, all outcomes are analyzed simultaneously. The importance of
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MVMA comes when two or more related outcomes within the same study are of interest.
The relationship between these outcomes is known as the “within-study correlation”
while the relationship between the outcomes across studies is known as “between-studies
correlation.” Both within and between study correlations are assumed to be “zero” in
UVMA, neglecting the relationships between the multiple outcome measures. Looking
closely at the MVMA fitting models discussed earlier, it can be noticed that the withinstudy covariance (correlation) 𝜌𝑖 appears on the total variance matrix (∆̂ + 𝑆𝑖 ) and more
specifically the inverse of this matrix (∆̂ + 𝑆𝑖 )−1. 𝜌𝑖 is involved through the total
variance matrix which in turn is involved in treatment effect and the heterogeneity
covariance matrix computations. Therefore, 𝜌𝑖 should have some impact on the
estimation of the MVMA such as producing estimates that have smaller standard errors as
well as improving the estimation of the between-study variances. As a result, we should
generally expect more precise estimates (Jackson et al., 2011). This effect, however, has
not been found in the literature.
As in MANOVA, MVMA allows us to measure several dependent variables
simultaneously which will increase the probability of discovering which outcome is truly
important. Additionally, using MVMA could decrease the chance of committing Type I
errors that might occur if multiple UVMAs were conducted independently. Lastly,
differences that are not discovered by UVMA could be revealed by using MVMA (French
et al., 2008). MVMA models depend on iterative procedures rather than closed-form
analytical solutions in the estimation of the parameters. Based on that, knowing when
MVMA is ideal to use and when it would give different estimates compared to UVMA is
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difficult to reach analytically (Ishak et al., 2008). In this case, conducting simulations
would be more efficient and would help in finding cases when MVMA is ideally utilized.
Advantages and Disadvantages of MVMA
Several advantages are offered by MVMA that make it superior to separate
UVMA of each outcome, which are conducted under the assumption of independent
outcomes (Riley, 2009). According to Jackson et al. (2011), the utilization of MVMA
methods can be beneficial and can provide estimates with better statistical properties than
UVMA. However, these benefits in return require meeting more assumptions which may
not result in better inference in every case. Typical assumptions made with MVMA are
(a) the multivariate normality assumption, (b) a multivariate linear relationship between
outcomes, and (c) a constant between-studies covariance matrix. However, for instance,
the multivariate normality assumption is usually hard to uphold. Furthermore, a linear
relationship between studies’ effects is needed since it is hard to estimate nonlinear
relationships with a limited number of studies.
Researchers may obtain different conclusions when using MVMA compared to
UVMA. Jackson et al. (2011) stated that conclusions drawn from a MVMA might
sometimes vary from those from a UVMA. The authors supported their claim using an
example where the aim was to describe the relationship between fasting glucose levels
and cardiovascular disease. The univariate meta‐analysis yielded a significant log hazard
ratio; however, the multivariate meta‐analysis gave a lesser, non‐significant log hazard
ratio. Carrying out a single MVMA would be more efficient than doing many univariate
ones. All MVMA parameter estimates are simultaneously provided in a single analysis.
Therefore, it would be easier to compare the results from different outcome variables
16

which may lead to a different conclusion than from separate UVMAs. Additionally, the
researchers reported that the utilization of a MVMA method could reduce bias due to
partial reporting since in UVMA, studies that do not have all the variables of interest are
excluded.
The quality of the estimates of MVMA and UVMA has been compared in
situations with two parameters. In the fixed- and random-effects meta-analysis, as the
number of parameters increases, MVMA benefits can increase substantially. However, in
the case of the random-effects meta-analysis and when high between-study variability is
present, the possible improvement would be small. When all studies have a common
between-study covariance matrix, the covariance matrices become even more similar as
between-study variance increases, reducing the benefit of MVMA (Boca et al., 2017).
Additionally, the actual improvement with MVMA is further shrunken by the need to
estimate an increasingly large between-study covariance matrix. Also, when the betweenstudy variability is minimal, or zero, the loss of the effectiveness by choosing randomeffects meta-analysis over fixed-effects meta-analysis increases as the number of
parameters increases (Boca et al., 2017).
The importance of MVMA is highlighted when there is more than a single
outcome of interest, which might present a challenge since the within‐study correlations
must be present. Knowledge of the within‐study correlations is usually unavailable in
practice since the correlations are not typically reported. In order to address this
limitation, several analysis methods for dealing with unknown within-study correlations
have been proposed. Wei & Higgins (2013) proposed an approach for the approximation
of the within-study covariances based on data about possible correlations between
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outcomes under study. The authors argued that when heterogeneity of effects across
studies is present and when there is a high correlation within studies, the proposed
approach to approximation of covariances performs better than others. Another method
was proposed by Y. Chen et al. (2016) that introduced a simple non‐iterative method. The
authors claimed that the method could be helpful for MVMA since the within‐study
correlations are not required for the analysis. The proposed method is based on the use of
standard univariate methods for the marginal effects as well as producing a joint
inference for multiple parameters. In addition, the researchers stated that, based on
simulation studies, the proposed method provides unbiased estimates, good estimated
standard errors, and good confidence intervals. This method is claimed to have high
relative effectiveness when compared with classic MVMA where the within‐study
correlations are known. In a recent study by Lin & Chu (2018), a new approach called
“multivariate meta-analysis of multiple factors” has been introduced to synthesize data
from all available factors simultaneously. The authors claim that MVMA of multiple
factors can improve statistical efficiency and reduce biases compared with separate
analyses by carrying information across factors. A Bayesian hybrid model is used to
conduct MVMA of multiple factors in order to account for both within- and betweenstudy correlations (that are usually unavailable from published articles). The performance
of MVMA of multiple factors and the traditional methods were compared by the
researchers using simulations. The hybrid model was found to be effective in reducing
complexity by specifying a joint marginal correlation matrix for all studies. However, the
researchers stated that if the collected studies’ marginal correlation matrices vary
extremely, a poor fit might be produced by the hybrid model.
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Despite these challenges, MVMA has been successfully applied in many different
settings. It has been used increasingly in the educational and medical sciences. In
education, for instance, MVMA has been applied in numerous studies in order to assess
the effects of an intervention. For example, evidence for Classroom Management SelfEfficacy (CMSE) in relation to three dimensions of burnout: emotional exhaustion,
depersonalization, and (lowered) personal accomplishment was examined using a
MVMA. The authors stated that their study was the only meta-analysis that examined
classroom management self-efficacy and teacher burnout; additionally, they stated that it
was the first MVMA conducted within the educational psychology field. The use of
MVMA was adopted in this study since they had three outcomes (dimensions of burnout
using a measure of association) and MVMA allowed the inclusion of the correlations
among the three dimensions of burnout. The results suggested that there was a significant
relationship between classroom management self-efficacy and the three dimensions of
burnout, meaning that teachers with lower levels of CMSE were more likely to
experience the feelings of burnout and vice versa (Aloe, Amo et al., 2014). In a similar
study, (Aloe, Shisler, et al., 2014) explored the relationship between student misbehavior
and the same three dimensions of teacher burnout (i.e., emotional exhaustion,
depersonalization, and personal accomplishment). They included a total of 21
independent studies and the results suggested that students' misbehavior was significantly
associated with the three dimensions of teacher burnout.
The use of MVMA has also increased in clinical research where multiple
outcomes are likely to be the case. MVMA can play an essential role in determining
which treatment should be recommended for a specific condition. For instance, a study,
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conducted by Del Re et al. (2013), reported that an earlier review found that the effect
sizes of oral naltrexone, which is an FDA-approved medication for treating alcohol use
disorders on relapse to heavy drinking and, to a lesser extent, percent days drinking, were
smaller in more recent trials and in multicenter trials than in single-site studies. They
examined whether these results apply when considering studies from 2004 to 2009 and
whether single-site versus multicenter trials, the use of placebo run-in periods, and
placebo group improvement accounted for variation in naltrexone effects and reducing
effects over time. In another example of a study that used MVMA in a clinical setting, the
power of a MVMA was evaluated by applying the method to existing two-dimensional
gel electrophoresis data from human prostate and colon tumors to extract valuable
information since numerous cancer two-dimensional gel electrophoresis studies have
stated partially redundant lists of differently expressed proteins. Fourteen proteins were
identified with a common trend between the tumor types (prostate and colon). By
utilizing multivariate meta-analysis, a common protein profile for two malign tumor
types was successfully determined, which would not be the case if data sets were
analyzed separately (Rosenberg et al., 2010). In a more recent study that used MVMA for
a clinical goal, Y. Q. Zhang et al. (2017) evaluated the severe effects of daily mean
temperature, cold spells, and heat waves on stroke mortality in 12 counties in China.
Researchers gathered data associated with daily mortality from stroke and meteorology in
the 12 counties through 2009-2012. In this study, a MVMA was utilized in order to
understand the community-specific associations between temperature and stroke
mortality. In addition, they were also interested in understanding the effect of cold- andheat-associated risks on mortality at different lag days. There are numerous additional
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multivariate studies that have been applied in different settings, but for the present study
purpose only a few examples have been discussed.
Comparisons of MVMA and UVMA
In meta-analysis, it is very common to have multiple outcomes that can be
analyzed separately by conducting independent meta-analyses (UVMA) or by analyzing
them jointly in a single model (MVMA). In this section, I review articles that aimed to
compare separate (UVMA) with joint (MVMA) meta-analysis.
Trikalinos and Olkin (2012) showed an example of a comparison of the
multivariate model with the UVMA at multiple time-points. They found that the results of
UVMA and MVMA analyses were almost identical, with a slight difference in the values
of the effect sizes and the relative standard errors. They reported that when the withinstudy covariances are zero or are all equal, estimates were the same in MVMA and
UVMA. However, they noted that the standard errors of the estimates were generally
slightly different between UVMA and MVMA.
Simulations have been used to compare UVMA with MVMA. Trikalinos et al.
(2013) conducted a comparison using real data and a simulation study. The Cochrane
Library of Systematic Reviews was screened to identify UVMA studies of categorical
outcomes that could be jointly analyzed (MVMA). The data were then analyzed with
UVMA and MVMA. The summary estimates and the relative standard errors of the
UVMA and MVMA were compared in an accompanying simulation study. The difference
in summary effects and their confidence intervals between UVMA and MVMA was
almost always small in both the empirical sample and the simulation study. The author
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suggested using MVMA in estimating differences between outcome-specific summary
treatment effects.
The performance of the MVMA approach was compared with the common
UVMA inverse-variance weighted approach in an extensive simulation. The study
explored different meta-analytic scenarios of genetic association studies of correlated end
points. In this simulation, the findings suggested that the performance of the MVMA
approach produced similar or better estimates than the UVMA method when the withinor between-studies correlations are at least moderate. The study showed that the MVMA
approach yields smaller bias and root mean square error (RMSE) estimates (Neupane &
Beyene, 2015).
Another comparison study was conducted by Lin and Chu (2018) utilized
Bayesian multivariate meta-analysis. The Bayesian MVMA made it feasible to import
informative prior distributions, specifically on correlations in the MVMA model. In this
study, the Bayesian MVMA was used to synthesize data on correlated outcomes in
rheumatoid arthritis and to embody informative prior data in the model. A Bayesian
hybrid model was used to perform MVMA since it accommodates both within- and
between-study covariances which are commonly unavailable from published articles. The
five-dimensional health-related quality of life measure (EuroQol) was used to map the
estimates of a health assessment questionnaire, and then the effect was compared with
mapping the health assessment questionnaire obtained from the UVMA. UVMA yielded
larger bias and root mean square errors. The hybrid model that was used effectively
minimized model complications by assigning a common marginal correlation matrix for
all studies.
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By reviewing the literature, it appears that results are consistent in that the use of
MVMA would increase the quality of the estimates and allow the inclusion of extra
studies. Also, results agreed that even though the within and between study correlations
were taken into account, the summary estimates of UVMA and MVMA were almost
identical, with no explanation found regarding this. The literature suggested using
MVMA when the within- or between-studies correlations are at least moderate, might
produce similar or sometimes better estimates compared to UVMA. The question that
one might ask here is why estimates do not vary much when comparing UVMA and
MVMA. If UVMA gives similar summary estimates compared to MVMA, should
MVMA still be used given that it entails more assumptions which can cause estimation
difficulties? Finally, by conducting separate UVMA, several studies will be excluded and
if the correlation between studies is assumed to be zero, how significant would that
exclusion (resulting in a reduced sample size) be that on the estimates of statistical
quality? The impact of between-study correlation and data missingness has yet to be
clearly determined.
Clinical Decision Support Systems (CDSS) and Diabetes Care Management
Diabetes care management is critical since unwatched or untreated diabetes could
result in severe complications that may damage many vital organs and most likely lead to
premature death (Centers for Disease Control and Prevention (CDC), 2000). One of the
approaches to diabetes care management explored in this study is use of clinical decision
support systems (CDSS). Conclusions of systematic reviews studies that reviewed
CDSSs had inconsistent conclusions (Jia et al., 2019a). Therefore, there is a need to
evaluate the CDSSs empirically which could improve the integrity and accuracy of the
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research. As an assistant lecturer at the University of Benghazi, department of health
informatics, I had been working closely with a public health specialist. CDSSs
implementation in the Libyan health system was always in debate since the effectiveness
of CDSSs is still uncertain. A study that confirms whether the use CDSSs is effective or
not will help in making a decision regarding their use. It has been shown that clinical
decision support systems have improved in their design, utilization, and effectiveness to
manage and improve quality of diabetes care. Current CDSSs have high use rates and
high clinician/user satisfaction rates. Also, the use of CDSSs has significantly improved
blood pressure control, glucose control, and cardiovascular risk trajectories in diabetic
patients. Based on that, CDSSs will likely become essential technologies that help to
guide clinician and patient decision-making (Patrick J. O’Connor & Sperl-Hillen, 2019).
A considerable amount of literature has been published where MVMA was the
primary analysis method. However, the goal of this study is to compare the effect size
estimates of MVMA and UVMA in the context of CDSS use in improving the quality of
diabetes care. Therefore, the researcher next sheds light on studies that examined the
impact of different CDSSs in order to get a clear picture of the use of the CDSSs and
their benefits regarding the quality of diabetes care prior to conducting MVMA and
UVMA on CDSS studies. The sequence of the review starts with a summary of studies
that examined a specific CDSS in improving diabetes care in order to get an initial insight
into whether the use of CDSSs was beneficial or not. Later, systematic reviews that
discuss the benefits of using CDSSs in enhancing diabetes care are reviewed in order to
reach a more general conclusion from narrative reviews and UVMAs.
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The effect of CDSSs in improving different conditions has been explored in
numerous studies. However, limited studies have discussed the effectiveness of CDSSs in
enhancing the quality of diabetes care. A recent study examined the effect of an
electronic health record-based clinical decision support tool on diabetes management in
primary care practices participating in Delaware's patient-centered medical home project
(Gill et al., 2019). In the quantitative analysis phase, bivariate analyses were conducted to
describe the data and to compare outcome measures for patients in the groups. Glycemic
and lipid control were analyzed using multivariate regression analyses to control for
possible confounding factors. Qualitatively, the staff at each primary care office were
interviewed and a research assistant summarized the interview transcripts. One of the
authors reviewed and interpreted all results and put together the concluding summary. In
sum, the researchers found that the use of clinical-decision-support systems was linked
with superior improvements from baseline in hemoglobin A1c and low-density
lipoprotein cholesterol. Based on the interviews, physicians and staff stated that the
clinical decision support toolkit allowed them to be more engaged in clinical decisionmaking and thus helping to improve diabetes care (Gill et al., 2019).
Management of diabetes, which is considered a complex chronic disease, may
require the integration and the understanding of multiple laboratory test results.
Traditional electronic health records tend to visualize lab results in a disorganized and
separated way which makes the interpretation of results associated with diabetes care
challenging. Sim et al. (2017) developed a diabetes-specific CDSS interface that displays
glycemic, lipid, and renal function results. The CDSS graphically summarized all related
laboratory results and presented them in a color-coded system which allowed easy and
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quick interpretation of the metabolic control of the patients. It also has an alert module
that notifies users of any tests that had to be rerun. An interactive graph module was
added to the CDSS for better graphical visualization of the trends of the lab results. In a
pilot study, the developed CDSS significantly improved the understanding of abnormal
laboratory results when compared to the existing laboratory reporting interface. However,
no significant improvement was found in the identification of patients needing treatment
modification. The researchers reported that the diabetes-specific CDSS interface they
developed could improve the management of diabetes and they expected that this CDSS
would be helpful when applied in an outpatient setting.
The implementation of electronic health records (EHR) is assumed to improve the
quality of ambulatory care, especially for chronic clinical conditions such as diabetes.
However, there had been no comparative studies of longer-term observation of the
quality of care in practices using electronic health records with those using paper records.
To address this gap, Crosson et al. (2012) examined data collected over three years to
conduct this comparison. Some practices had utilized electronic health records previous
to initial data collection and kept using the system during the observation period, while
the other practices used the typical paper records. They analyzed data from 16 practices
that utilized electronic health records and 26 that did not. Measures of care were
evaluated for 798 patients with diabetes. They also noted that they used hierarchical
linear models to examine the relationship between electronic health records use and
obligation to evidence-based diabetes care guidelines. Hierarchical logistic models were
also used in order to compare rates of improvement over three years. Electronic health
records use was not significantly related to better adherence to care guidelines. Patients in
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practices that did not use an EHR were more likely to meet all three intermediate
outcomes goals for hemoglobin A1c, low-density lipoprotein cholesterol, and blood
pressure at the 2-year follow-up. However, the quality of diabetes care improved among
all practices. As a conclusion of their study, the authors stated that consistently using
EHR over three years might not successfully improve the quality of diabetes care.
In some cases, CDSSs provide information that can be shared and discussed by
both patient and physician which might improve the management of diabetes. However,
according to Holbrook et al. (2009), this has rarely been examined in community-based
primary care. Based on that, Holbrook et al. conducted a study in order to assess the
effectiveness of a Web-based diabetes color-coded tracker shared between patient and
primary care providers in improving the quality of diabetes management in communitybased primary care. The researchers randomly assigned adult primary care patients with
type 2 diabetes to obtain either the intervention or traditional care. Forty-six primary care
providers were sequentially recruited and 511 of their patients. A significantly better
process composite score was found for patients in the intervention group compared to
control patients. They reported that 61.7% of patients in the intervention group showed
improvement compared to an improvement of 42.6% of the control group patients.
Additionally, a significant improvement was found in more variables in the intervention
group. A significantly higher decline was also found in blood pressure and glycated
hemoglobin in the intervention group patients. Greater satisfaction with their diabetes
care in the intervention group patients was reported. As a conclusion, the researchers
stated that the shared electronic decision-support system improved the process of care
and some clinical indicators of the quality of diabetes care.
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Continuing with CDSS evaluation, in a study by P. J. O’Connor et al. (2011), an
electronic health record-based diabetes clinical decision support system was evaluated.
The goal was to explore its impact on the control of hemoglobin A1c (glycated
hemoglobin), blood pressure, and low-density lipoprotein (LDL) cholesterol levels in
adults with diabetes. In this study, a clinic-randomized trial was conducted where 11
clinics with 41 primary care physicians and 2,556 patients with diabetes were included.
Patients were randomly assigned to either intervention group (receive) or control group
(not to receive) an electronic health record-based clinical decision support system.
General and generalized linear mixed models with repeated time measurements were
utilized in order to comply with the nested data structure. Patients in the intervention
group had significantly better hemoglobin A1c, systolic blood pressure control, and
slightly better maintenance of diastolic blood pressure control. However, no improvement
was detected in low-density lipoprotein cholesterol levels compared to patients in the
control group. The researchers concluded that electronic health record-based diabetes
clinical decision support has a significant effect in improving glucose control and
partially improved blood pressure control in patients with type 2 diabetes.
Coronary artery disease (CAD) is a significant factor in the long-term prediction
of disease progression in patients with diabetes mellitus (DM) and examining the impact
of a CDSS in improving the care of these patients is important (Aronson & Edelman,
2014). Several studies have examined the possible effect of using CDSSs for this
condition. In an evaluation of the impact of two different CDSSs in improving and
addressing deficiencies in the care of patients with coronary artery disease and diabetes
mellitus, Sequist et al. (2005) aimed to examine the effect of an integrated patient28

specific electronic clinical reminder system on diabetes care. They were also interested in
evaluating the impact of the introduced CDSS on coronary artery disease care. A total of
194 primary care physicians, 4549 patients with diabetes, and 2199 patients with
coronary artery disease at 20 ambulatory clinics were included in the study. Clinics were
randomly assigned to the intervention so that physicians received either evidence-based
electronic reminders or typical care. The researchers found that electronic reminders
increased the chances of recommended diabetes and coronary artery disease care.
However, the effect of individual reminders was inconsistent. In general, the researchers
argued that an integrated electronic reminder system led to an improvement in care for
both diabetes and coronary artery disease.
Following a complex medication routine might cause a struggle with self-care and
in managing blood glucose levels for patients with diabetes. In a study by Schnipper et al.
(2010), the goal was to evaluate a new documentation-based CDSS (Smart Form)
effectiveness in addressing deficiencies in the care of patients with coronary artery
disease and diabetes mellitus. In their controlled randomized trial, they randomly
assigned primary care physicians in 10 ambulatory practices to usual care or the coronary
artery disease /diabetes mellitus Smart Form. Patients of intervention primary care
physicians had a better proportion of deficiencies addressed compared with controls. The
authors stated that the use of the Smart Form was limited, and a modest improvement in
management was detected (Schnipper et al., 2010; Sequist et al., 2005).
Medication nonadherence is common among patients with diabetes mellitus and
relates to critical adverse results. Therefore, interventions are needed in order to improve
medication management so patients can achieve the promising benefit of prescribed
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treatments (Ho et al., 2006). As a contribution to that, Morrow et al. (2012) conducted a
project that aimed to improve self-management of medications and related health
outcomes by introducing system support. They presented an Electronic Medical Record
(EMR)-integrated system designed to enhance patient-physician collaboration required
for medication management. The researchers said that the new EMR “helps providers and
patients work together to create effective medication schedules that are easy to
implement” (Morrow et al., 2012). The researchers stated that an evaluation study to
examine the usefulness of the Medtable™ in improving care control condition among
diabetic patients struggling to manage multiple medications was planned. However, the
effectiveness of Medtable™ has not been evaluated yet.
CDSSs have been widely used in developed countries and their effects have been
evaluated in many studies. However, only a few works in the literature demonstrate the
effectiveness of CDSSs in developing countries. In Brazil, a study was conducted to
analyze the possibility, usability, and clinical influence of a clinical decision support
system in Brazilian primary care diabetes patients. A quasi-experimental design was
performed and type-2 diabetes primary care patients older than 40 years of age were
included. Patients were evaluated before and after the implementation of the CDSS. The
CDSS application included clinical assessments and blood glucose measurements and
produced detailed recommendations built on the data analyzed. The total number of
patients included was 145 patients and 70.0% of them had been diagnosed with diabetes
more than five years ago. There was no improvement found in median hemoglobin A1c.
The subgroup analysis showed that a significant decrease in median hemoglobin A1c
level was observed in patients with a hemoglobin A1c level of ≥ 9% at baseline.
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However, this reduction happened before the implementation of CDSS. Healthcare
practitioners stated that the CDSS was easy to use and claimed that it provided valuable
information for patient care. However, it was concluded that the implementation of the
CDSS did not improve the hemoglobin A1c level, and that might have happened because
of the short follow-up and/or infrequent CDSS use by the healthcare practitioners (Xavier
et al., 2016). Another study conducted in India by Prabhakaran et al. (2019) evaluated an
integrated CDSS for multiple chronic condition management in primary care. The
researchers were specifically interested in assessing the impact of a “mHealth system
mWellcare” for the integrated management of hypertension, diabetes mellitus, current
tobacco and alcohol use, and depression compared to the improved usual care among
patients with hypertension and diabetes mellitus in India. Community health was
randomly assigned to either receive the “mWellcare” or improved usual care. The result
of this cluster-randomized controlled trial that involved 40 community health centers
yielded a non-significant difference between the two groups for systolic blood pressure
and glycated hemoglobin. Likewise, there were no differences between the two groups
regarding tobacco and alcohol use or other secondary outcomes. As a conclusion of this
study, the researchers concluded that the use of “mWellcare” was not beneficial in the
management of the chronic conditions studied.
The evaluation of CDSSs remains limited. More research is needed in developing
countries to reach an accurate conclusion about whether the use of CDSSs improves the
quality of care in these countries.
Numerous randomized and non-randomized controlled trials have been conducted
on the topic and several systematic reviews (not meta-analyses) discussed the findings. A
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review conducted by Garg et al. (2005) aimed to review randomized and non-randomized
controlled trials that evaluated the impacts of computerized CDSSs. Their data were
based on searching the MEDLINE, EMBASE, Cochrane Library, Inspec, and ISI
databases as well as checking reference lists through September 2004. For inclusion
criteria, the authors included all randomized and non-randomized controlled trials that
assessed the effect of a CDSS compared with care given without a CDSS on practitioner
performance or patient outcomes. The researchers found one hundred studies that met
their inclusion criteria. They found that CDSS improved practitioner performance in 62
of the 97 studies evaluating practitioner performance. Regarding patient outcomes, they
found that 52 studies evaluated one or more patient outcomes with only seven trials
stating that patient outcomes were improved. The researchers concluded that many types
of CDSSs improved practitioner performance. However, they reported that the effect on
patient outcomes was inconsistent. Finding systematic reviews and meta-analysis on this
topic is extremely beneficial since high-quality evidence and extensive references to
primary studies relevant to the research topic are provided. However, there is a very
limited number of relevant systematic reviews and meta-analysis studies.
A systematic review and meta-analysis conducted by Jeffery et al. (2013) that
reviewed randomized trials evaluated the effects of computerized CDSSs in ambulatory
diabetes management compared with a non-computerized clinical decision support
system control. They used a comprehensive computerized CDSS overview conducted in
January 2010. They used EMBASE, MEDLINE, INSPEC/COMPENDEX and EvidenceBased Medicine Reviews (EBMR) from January 2010 to April 2012 in their search. In
addition to the previous sources, reference lists of related reviews included articles and
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Clinicaltrials.gov were also used in their search. Based on the researchers’ inclusion
criteria, randomized controlled trial studies of diabetes in ambulatory care settings that
also compare a computerized CDSS intervention with a non-computerized CDSS control
and measuring either a process of care or a patient outcomes were included in the review.
Two reviewers were independently responsible for screening of studies, data extraction,
and evaluating risk of bias and quality of evidence assessments. The systematic review
included 15 trials. Hemoglobin A1C (HbA1c) and quality of life and hospitalization were
all not statistically significant, but all favored the computerized CDSSs over the control.
Computerized CDSSs were also superior compared to control in terms of triglycerides
and practitioner performance. Even though outcomes seem to be leaning toward support
of computerized CDSS interventions, the effects were small, and the quality of the
evidence was low. Additionally, no improvements were detected in important patient
outcomes. The researchers concluded that a marginal improvement in clinical outcomes
might be gained by utilizing computerized CDSSs in diabetes management. However,
they claimed that because of the risk of bias, inconsistency, and imprecision, confidence
in the evidence is low.
Another review of randomized controlled trials of medical record powered CDSSs
to improve the quality of diabetes care was performed by Ali et al. (2016). The goal was
to evaluate the effectiveness of CDSSs in improving quality of type II diabetes care.
Inconsistent and variable results for the quality of diabetes care measures were found in
the review. The process of care for all three measures of quality (Glycated hemoglobin
(HbA1c), low-density lipid cholesterol (LDL-C), and blood pressure (BP)) of diabetes
care were significantly improved. However, weak to modest positive results were
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observed for the clinical measures of the diabetes care indicators. In addition to this, the
technology adoption of CDSS was found to be consistently low.
Some systematic reviews have shown that CDSSs have potentially improved
diabetes care. However, it is not clear whether CDSSs are effective in improving diabetes
management care since different methods of measuring and presenting outcomes were
used with inconsistent conclusions. In order to address this issue, Jia et al. (2019) in their
recent work conducted a comprehensive overview to evaluate the effects of CDSSs on
diabetes care as well as examining methodological and reporting qualities. PubMed,
EMBASE, and Cochrane Library were the primary search sources through February
2017. The researchers included systematic reviews that examined the effects of CDSS on
diabetes care. The outcomes in the overview were defined and evaluated separately for
the process of care and patient outcomes. Methodological quality was assessed by an
instrument for critically evaluating systematic reviews of randomized controlled clinical
trials (“AMSTAR”) and reporting qualities were assessed by an evidence-based
minimum set of items for reporting in systematic reviews and meta-analyses
(“PRISMA”). The total number of systematic reviews included was 17 studies. These
studies had 222 unique randomized controlled trials and 102 non-randomized controlled
trials. In 32 of 102 unique studies, CDSSs were found to be significantly effective in
improving patient outcomes. The process of care was found in 117 out of 143 unique
studies to be substantially affected by CDSS. Overall scores of AMSTAR resulted in a
mean score of 6.5 where AMSTAR ranged from 8 to 11 is considered high quality, 4 to 7
is of medium quality, and 0 to 3 is low quality (Sharif et al., 2013). As a conclusion of
this comprehensive overview, the researchers claimed that CDSSs improved the quality
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of diabetes care by improving the process of care or patient outcomes. There was also
evidence that CDSSs that provide alerts, reminders, or feedback to participants were most
likely to influence diabetes care. However, poor reporting of methodological domains
and qualitative or narrative methods to combine findings was reported.
The effect of the CDSSs has been evaluated in numerous studies and the results
are not consistent. Additionally, several systematic reviews have studied the effect of the
CDSSs. However, a statistical procedure to combine the numerical data from multiple
separate studies is needed. Therefore, conducting a MVMA will help to get a clearer
picture and more precise and powerful results.
Purpose of the Study
MVMA is becoming more commonly used, especially in clinical research where
there is no single, “gold standard” outcome measure. In sum, it has been suggested that
MVMA obtains estimates for all effects under study simultaneously, defines the
relationship between the effects, and provide estimates with better statistical properties
(i.e., lower standard errors) than univariate meta-analysis. Even though MVMA can be
useful and provide better statistical estimates, these benefits could depend on making
additional assumptions regarding both what is reported in source studies and also about
the nature of the data. MVMA requires within and between study correlation estimates
which are not always available. Despite the additional complications and issues the
MVMA brings, it can make a real contribution to the field of meta-analysis (Jackson et
al., 2011)
Reviewing the literature leads to the gap previously discussed. Although some
authors have conducted comparative studies, the question of why the results
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produced by MVMA with the consideration of the correlation and univariate metaanalysis are almost identical is insufficiently explored. In order to address this issue
and after reviewing the formulas of UVMA and MVMA to get a better understanding of
how both methods are constructed, a simulation study was utilized to see how and when
estimates produced by MVMA would be different and more statistically precise
compared to estimates produced by separate UVMAs. In this simulation, three factors
were allowed to vary. Sample size had three levels, the percentage of missingness had
three levels, and finally the between-study correlation had two levels. The effect sizes
were generated using standardized mean differences to simplify the comparison
procedure. In addition, no one to the best of the researcher's knowledge has applied
MVMA to study the effect of CDSSs. Therefore, to address these gaps in the literature,
the researcher applied MVMA and UVMA to examine the effects of CDSSs on the
quality of diabetes care management and explore reasons behind the similarity and
differences in the effect estimates of the two methods.
Definition of terms
Coding
Coding is a procedure that extracting information necessary to perform a metaanalysis
from the primary studies (Card, 2015).
Effect size (EF)
EF is a standardized scale-free estimate of the relationship between an exposure
and an outcome. Any difference in the outcome between the study groups such as mean
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differences, relative risk, odds ratio, and risk difference could be defined as an effect
sizes (Delgado-Rodríguez, 2001).
Exclusion criteria:
Exclusion criteria is a criterion that is used by the researcher in order to specify
which studies should be excluded from a meta-analysis.
Fixed-effects model (RE)
In FEM, effects are assumed to be homogeneous across the studies in which effect
sizes have a common true value for all studies (Delgado-Rodríguez, 2001).
Funnel plot
A funnel plot is a graphical method to display any possibility of publication bias.
It simply displays the relation between the effect size of the study and its size. When
publication bias is not exists, the funnel shape should be symmetric (Delgado-Rodríguez,
2001).
Heterogeneity
Heterogeneity means that there is between study variation. When there is
heterogeneity, it means that there could be more than one true effect sizes in the
combined studies (Delgado-Rodríguez, 2001).
Inclusion criteria
Inclusion criteria is a criterion that is used by the researcher in order to specify
which studies should be included in a meta-analysis.
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Gray literature
Gray literature is rarely included in meta-analyses. These kinds of literature are
not controlled by commercial publishers. Gray literature typically has a limited
dissemination and are difficult to be retrieved (Card, 2015).
Meta-analysis (MA)
Meta-analysis can be defined as a statistical method to calculate an overall effect
of single, independent studies by systematically synthesize their findings (Shorten &
Shorten, 2013).
Univariate meta-analysis (UVMA)
In UVMA treatment effects for multiple outcomes are meta‐analyzed separately
ignoring the possible correlation between the effects (Trikalinos et al., 2014).
Multivariate meta-analysis (MVMA)
MVMA is an extension of the standard UVMA. In MVMA, effect estimates are
jointly synthesized which allows for the accounting of within-study and between-study
correlations of the outcomes (Jackson et al., 2011).
Publication bias
Publication bias could happen when the published studies carried out on a specific
topic do not represent all the relative studies (Delgado-Rodríguez, 2001).
Random-effects model (REM)
Unlike FEMs, the REM does not assume that the effects across studies being
pooled are homogeneous. That means that each sample of studies has it is own a true
effect size (Delgado-Rodríguez, 2001).
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Chapter Two
Method
In this chapter, I first describe how data were simulated to examine the effects of
sample size, amount of missing data, and between-study correlation on the estimates of
UVMA and MVMA when they are allowed to vary. I then describe the process used in
terms of steps taken to perform the meta-analysis.
Data Simulation
Before I empirically compared UVMA and MVMA using real data, I conducted a
simulation which allowed me to control some variables and hold others constant in an
attempt to understand when the utilization of MVMA (where two or more outcomes are
simultaneously analyzed), gives more precise estimates. For data simulation, a Monte
Carlo simulation technique was applied. The Monte Carlo approach is a very common
technique to test theoretical hypotheses by generating datasets that meet specified
conditions (Paxton et al., 2001). In this simulation, two outcomes were considered for
simplicity. Outcomes one and two were set to have a true effect size of 0.7 and 0.5,
respectively. The sample estimates for the studies were generated from the normal
distribution using the true effect sizes while sample within study standard deviations were
generated from a gamma distribution. Variables that were manipulated were sample size,
between-study correlation, and the percentage of missing data. For sample size, and
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according to Jackson and Turner (2017), at least five studies are needed to
consistently gain power from random-effects meta-analysis. Therefore, sample size had
three levels--small = 5, medium = 20, large = 50 studies. The between-study correlation
had two levels (weak = 0.1 and strong = 0.9). Finally, the degree of missing data had
three levels (0%, 30%, and 70%). Missing data were generated to be MCAR.
Table 1 below shows a summary of the simulation conditions across all
manipulated factors, with 3x2x3=18 conditions.
Table 1
Summary of Conditions across the Varying Factors
Sample size

Small (5)

Medium (20)

Large (50)

Between-study correlation
Weak (0.1)
Strong (0.9)

Degree of missingness
0%

Weak (0.1)
Strong (0.9)

30%

Weak (0.1)
Strong (0.9)

70%

Weak (0.1)
Strong (0.9)

0%

Weak (0.1)
Strong (0.9)

30%

Weak (0.1)
Strong (0.9)

70%

Weak (0.1)
Strong (0.9)

0%

Weak (0.1)
Strong (0.9)

30%

Weak (0.1)
Strong (0.9)

70%

40

In each scenario, the generated data were used to conduct UVMA and MVMA.
The result in each scenario then was compared in terms of the statistical properties (i.e.,
how different are the outcome estimates? are there any standard error and confidence
interval improvements? is there any change in conclusions?). To analyze results of this
simulation study, a 3x2x3 three-way analysis of variance (ANOVA) was used in order to
examine main effects and interactions among the three factors for each of the two
dependent variables, ES = .7 and ES = .5. Subsequently, a further 2x3x3 (method x
missingness x sample size) MANOVA was conducted to compare results of methods
UVMA and MVMA directly. A MANOVA was used to simultaneously analyze ES = 7
and ES = .5 as the two dependent variables. In this analysis, the between-study
correlation factor was eliminated as it did not apply to the UVMA and further, it showed
little effect in the ANOVAs.
The simulations for all scenarios were conducted using the R statistical software
program (R Core Team (2020). For each scenario 1,000 simulation runs (replications)
were carried out in order to reach sufficient and stable estimates (Belias et al., 2019;
Carter et al., 2019; Huang et al., 2015; Mittlböck & Heinzl, 2006). Partial eta squared
(𝜂𝑝2 ) rules of thumb for small =.01, medium =.06, and large =.14 were used to identify
interpretable effects of the controlled factors rather than statistical significance due to the
large sample size. The missing data were only applied on the second ES = 0.5 in order to
see if the presence of missing data in one outcome could affect the other.
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Meta-analysis Procedure
Literature Search
In this study, multiple sources were used in the searching procedure, including
The Cochrane Controlled Trials Register (CCTR), PubMed which uses MEDLINE as a
primary database, checking of reference lists, and hand-searching of key journals. In
order to minimize publication bias, references in published studies, computerized
databases searching of unpublished material, conference proceedings, and graduate
dissertations were considered in the searching procedure (Ab, 2010).
Study Selection
In meta-analysis, in order to produce reliable results, randomized controlled trials
(RCTs) are usually used since they provide the highest level of evidence with least bias
(Ahn & Kang, 2018). Therefore, only RCTs of the effects of quality of diabetes care with
the use of clinical decision support systems were considered for inclusion. The keywords
that were used for the search include electronic medical record; electronic health record;
computerized clinical decision support system; quality of diabetes care; diabetes patient
outcomes; health information technology; cholesterol management; hyperlipidemia; lowdensity lipoprotein cholesterol. Boolean statements were utilized to either expand or
reduce the search recall and return a precise result. Published and unpublished RCTs
between 2010 and the present were included.
Table 2 below displays the search string that the researcher developed in order to conduct
the initial search.
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Table 2
Search Strings and Databases Used
DATABASE
PUBMED
(MEDLINE)
The Cochrane
Controlled Trials
Register (CCTR)

SEARCH STRING
(Health Information Technology OR HIT OR
Computerized decision support OR Electronic health
record) AND (diabetes care management OR diabetes
management) Filters: Randomized Controlled Trial
(clinical decision support) AND (diabetes care
management OR diabetes management) Filters:
Randomized Controlled Trial

FILTER
Date
published:
2010-present

Inclusion and Exclusion Criteria
There were two screening steps once the initial search of the prospective studies
was done. The purpose of these two screening steps is to enhance the efficiency of the
selection and avoid the risk of leaving out any pertinent studies. In the first step, the
abstracts of the articles were examined for their relevance. For instance, abstracts
containing the keywords “clinical-decision-support systems” and “diabetes care
management” were retained for the next step. Abstracts that did not contain such words
were still acceptable if they contained any other relevant indirect keywords.
The articles that passed step one then went through the second screening step. In
this step, articles were fully screened. Articles qualified to be included in the metaanalysis if they passed the exclusion criteria. The first criterion is that articles would be
excluded if they do not have empirical data, such as qualitative studies which do not hold
any experimental or empirical data. Secondly, articles would be excluded if they do not
provide enough statistics and data to estimate the required effect size and its associated
variance. The third exclusion criterion is that studies would be excluded if they do not
state at least one of the following indicators: LDL-C, HbA1c, or BP. Fourth, the study
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also would be excluded from the analysis if it does not mention the use of at least one
CDSS and does not include patients with diabetes mellitus.
Regarding grey literature and unpublished studies, ProQuest Dissertations was the
primary database used for searching the grey literature or unpublished studies. The search
string that was used in order to retrieve studies from ProQuest Dissertations was:
ab(clinical decision support systems) AND ab(diabetes)
In addition to ProQuest Dissertations, the National Institute of Health (NIH,
http://www.nimh.nih.gov/index) and OpenGrey (http://www.opengrey.eu/) were used in the
search for grey literature and unpublished studies. Figure 1 shows the flow diagram of the
search strategy and selection of articles.
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Figure 1
Flow Diagram of Search Strategy and Selection of Articles.
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Additional studies identified through
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Studies excluded
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45

Publication bias
To the best of my knowledge, no literature was identified that addresses a specific
method on how publication bias might be captured when a MVMA is used. Therefore, to
deal with any possible biases, this study considered the unpublished studies found by
using ProQuest Dissertations, HIB, and OpenGrey as search sources. Additionally, some
publication bias evaluations, such as funnel plots, Orwin’s fail-safe N, and p-curve
analysis, were used to evaluate publication bias (Card, 2015)
Sources of bias.
Typically, it is more likely that studies with statistically significant findings are
published compared to studies that report non-significant results. Those published studies
are found to have a larger effect size. The possibility of producing bias in the significance
of the effect sizes might be very large, especially if studies have relatively small sample
sizes. Therefore, published studies are more likely to be included in a meta-analysis
(Dickersin, 2005). If a researcher conducting a systematic review was able to find studies
that in the grey literature, then publication bias would not be a problem for meta-analysis.
However, this is not usually the case, for instance, looking in the first 1000 Cochrane
systematic reviews, it has been found that almost half of them contained no data from
grey or unpublished sources (Mallet et al., 2002).
Publication status is not the only source of bias, there are other factors that can
lead to a bias in effect size. First, language bias, where English-language databases and
journals are more likely to be searched. Secondly, availability bias, where the selective
inclusion of studies is more likely for those studies easily accessible to the researcher.
Third, cost bias where the selective inclusion of studies is more likely designed to include
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available free or low-cost studies. Similarity bias means the selective inclusion of studies
based on one’s own opinion. Another source of bias is duplication bias where studies with
statistically significant results are more likely to be published in more than one journal.
Finally, citation bias can exist where studies with statistically significant results are easier
to identify since they are more likely to be cited in other studies (Egger et al., 1997;
Gøtzsche & Johansen, 1997; Jüni et al., 2002; Ravnskov, 1992; Tramèr et al., 1997).
Bias diagnostics methods
Overestimation of the actual effect size is a problem when the studies in a metaanalysis are based on a biased sample of studies, and that should be accommodated.
Several methods have been designed to assess the potential impact of bias on a given
meta-analysis. Each one of these methods aims to answer specific inquires. The first
method is the funnel plot which detects evidence of bias (Light & Pillemer, 1984). The
second method is Orwin’s Fail-safe N. This method checks if the entire effect is an
artifact of bias (Orwin, 1983). Finally, Duval and Tweedie’s Trim and Fill method that
allows knowing the impact that the bias has (Duval & Tweedie, 2000). These three
methods are explained in more detail below.
Funnel plot
Funnel plots have been commonly used to check bias in meta-analyses. A funnel
plot is a scatter plot of the effect estimates from individual studies versus some measure
of each study’s size, which is usually the standard error of the effect estimate. If no bias is
present and there is between-study heterogeneity, the plot will follow a symmetric
inverted funnel. However, when the publication bias is present, the plot is symmetric at
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the top, with a few missing studies in the middle, and more missing studies close to the
bottom. (Sterne et al., 2011).
Orwin’s Fail-safe N
This method enables the researcher to discover the number of missing studies that
would lead the overall effect to a non-zero level. The researcher selects a value that
would represent the smallest effect assumed to be of substantive utility and determine
how many missing studies it would take to make the summary effect fall below this point.
Additionally, Orwin’s method allows the researcher to determine the mean effect in the
missing studies as a non-zero value (Becker, 2005; Begg & Mazumdar, 1994).
Duval and Tweedie’s Trim and Fill
Duval and Tweedie’s Trim and Fill approach allows estimation of the unbiased
effect. The idea of the approach is that it uses an iterative method to eliminate the most
extreme small studies from the funnel plot and, more specifically, the positive side and
computes the effect size at each iteration until symmetry is gained. As a result,
theoretically, this will produce an unbiased estimate of the effect size. It also shrinks the
variance of the effects, generating a narrow confidence interval. The original studies then
will be added back into the analysis and a mirror image for each will be imputed (Duval
& Tweedie, 2000).
In meta-analysis, it is essential to include an evaluation of publication bias in
order for the result to be robust and to guarantee the integrity of the individual metaanalysis. Ignoring the potential for bias might lead to the conclusion that the current
meta-analyses cannot be trusted.
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Variables and Coding
As mentioned in the introduction, three indicators (outcomes) were used in
UNMAs and MVMAs as a guide in assessing the quality of diabetes care. Those
indicators were low-density lipid cholesterol (LDL-C), glycated hemoglobin (HbA1c),
and blood pressure (BP). Reduction in these indicators reduces the risk of diabetes
complications and death (Hu et al., 2016b). In the following paragraphs, I briefly
summarize them and their recommended levels.
Low-density lipid cholesterol (LDL-C)
LDL-C, also called the bad cholesterol, is most of the body’s cholesterol. The risk
of heart disease and stroke increases as LDL cholesterol increases (CDC, 2020). A goal of
<100 mg/dl (2.60 mmol/l) for LDL cholesterol is recommended for patients with diabetes
without preexisting CVD according to The American Diabetes Association (ADA).
Glycated hemoglobin (HbA1c)
Glycated Hemoglobin (HbA1c) is used routinely to evaluate glycemic control in
diabetics to achieve treatment goals and limit long term complications. The ADA has
recently recommended the use of glycated hemoglobin (HbA1c) as an indicator to
diagnose diabetes mellitus (Tay et al., 2011). HbA1c levels ranged from 5.7% to 6.4%
indicates a higher risk of getting diabetes. Levels of 6.5% or higher mean you have
diabetes (Jagannathan et al., 2016).
Blood pressure (BP)
Blood pressure (BP) is the pressure of circulating blood on the walls of blood
vessels (Sa et al., 2014). It is recommended that a blood pressure goal is less than 130/85
mm Hg in patients with hypertension and diabetes mellitus (Bakris, 2001).
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Coding process
A typical code sheet and codebook was developed for the MVMA and UVMA.
The code sheets in this meta-analysis contained three primary categories of variables: (a)
methodological and substantive features; (b) study quality; and (c) outcome data.
Methodological and substantive features are significant variables to code in every metaanalysis. Information such as year of publication, type of research design, and inclusion
criteria is important to describe the literature and hence can relate these characteristics to
study findings (Sa et al., 2014). The strategy that was used in this study in order to
develop and adopt the coding sheet was a review of a random subset of studies to be
synthesized and adopting all related coding variables during the review. After including
the adopted variables, the coding sheet was pilot tested on a different subset of studies.
As soon as the development of the code sheet was completed, a codebook was developed
to lead the coding process (Brown et al., 2003).
Evaluation coding decisions
According to Card (2015), there are two essential qualities of the coding system
that are linked to aspects of transparency and replicability. Additionally, it is significant to
account for the reliability of the coding. In any meta-analysis study, enough details of the
coding process should be presented in order for the audience to know how the coding
decisions were made (transparency). Replicability is the ability approaching the same
coding decisions as the researchers did if an audience member were to use the coding
strategy the researcher developed to the studies included in the current meta-analysis
(Card, 2015).
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Coding reliability
Card (2015), has extensively explained the mechanism of evaluation of the
reliability of the coding. To empirically assess the replicability of the coding, the
reliability of independent coding procedure of the same studies was evaluated. There are
two ways to evaluate the reliability, either by using intercoder reliability or intracoder
reliability. Intercoder reliability is when reliability is evaluated between two independent
coders. Intercoder reliability is evaluated by having two independent coders assigned to
code a subset of overlapping studies. The number of the studies that coder should
independently code should be large to ensure an adequate estimate of reliability. A sample
of 20 to 50 studies is recommended and the researcher’s decision to choose a sample size
within this range should depend on the researcher understating of the coding interface
level. For example, a lower interface level suggests that a lower number of studies is
needed in order to confirm intercoder agreement and vice versa. In contrast, intracoder
reliability is when the evaluation occurs within the same coder. This approach is not ideal
in assessing the reliability of the coding system as Card (2015) noted that “ intracoder
agreement is not a perfect substitute for intercoder agreement because one coder might
hold potential biases or consistently make the same coding errors during both coding
sessions” (p.75).
Therefore, in this study, intercoder agreement was adopted as a reliability measure
of the coding and one Ph.D. student and the researcher coded a subset of overlapping
studies. The reliability was quantified using the Agreement Rate (AR). Even though AR
does not account for base rates of coding, according to Card (2015), it is the simplest and
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commonly used index of coding reliability. The intercoder agreement of this study was
88% which is considered very good agreement (Hartmann, 1977; Stemler, 2004).
Coding study characteristics
At least four characteristics should be coded as Card (2015) recommended. These
four study characteristics are: characteristics of the sample, measurement, design, and
source characteristics.
Regarding sample characteristics, aspects of sampling procedure and
demographic features of the sample were coded. Some characteristics that might be
coded are the setting, sampling technique, gender, socioeconomic status, etc. It is not
necessary to code all sample characteristics. The researcher only coded relevant
characteristics.
For measurement characteristics, according to Card (2015), knowing the strengths
and the weaknesses of the measurement processes would be extremely helpful in guiding
descriptions about what measurement characteristics should be coded. For instance, some
potential variables that might be coded are the source of information and specific features
of the measurement process.
Study-design characteristics is another set of characteristics that Card (2015)
recommended to code. Since only RCT studies were included, the type of RCT used and
aspects of the control groups were coded to have an idea about the design features.
Finally, coding whether the study is published or not is essential to evaluate evidence of
publication bias. As Card mentioned, coding the year of publication might be useful,
especially in the evaluation of year as a moderator to clarify any historic trends in the
effect size across time. More characteristics might arise when the actual coding procedure
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begins. Since studies that were included in this research are RCTs, the outcomes were
more likely to be a continuous variable. When there are treatment and control groups, the
mean difference is typically used to quantify the treatment effect (Cheung, 2013).
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Chapter Three
Results
Results from the data analysis are reported in this Chapter. First, the results of the
simulation are presented. After presenting the simulation results, the empirical study
comparison findings are presented. Finally, the evaluation of the effect of the CDSSs is
summarized.
Results of the simulation
Two-way ANOVAs of the UVMA Simulation
A two-way ANOVA was conducted to determine the effects of sample size and
percent of missing data on effect size coefficient estimation and the corresponding
standard errors. Due to the large sample size used in the simulations, partial eta squared
values were used to evaluate the importance of main effects and interactions instead of
statistical significance. Partial eta squared (𝜂𝑝2 ) rules of thumb for small =.01, medium
=.06, and large =.14 were used to interpret the main effects and interactions (Kittler et al.,
2007) with values of ≥.01 used to define interpretable effects.
Effect Size
Effect Size (.7). The results of the two-way ANOVA suggested that no effects of sample
size and percent of missing data that were at least small in magnitude were detected on
the effect size estimate of ES = .7 coefficient estimates (𝑝 = .41, 𝜂𝑝2 = .000), (𝑝 =.26, 𝜂𝑝2
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= .000), respectively (Tables 3 and 4). Moreover, the interaction between sample size and
percent of missing data was also negligible (𝑝 = .31, 𝜂𝑝2 = .001).
Table 3
Anova Summary Table for ES = .7
Sum of
Partial Eta Squared
(𝜂𝑝2 )
Squares
df Mean Square F
p
SZ
.02
2
.01
.90 .407
.000
Miss
.02
2
.01
1.29 .275
.000
SZ * Miss
.04
4
.01
1.19 .313
.001
Error
79.33
8991
.01
Total
79.41
8999
Note: SZ = Sample size (5,20,50); Miss = The percent of missing data (0%,30%,70%).
Table 4
Effect Size Estimate Means of ES = .7 by Levels of Sample Size
Sample Size
Small = 5
Medium = 20
Large = 50
Total

Mean
.699
.697
.700
.699

Effect Size (.5). Regarding the effect size estimate of ES = .5, the two-way ANOVA
showed that sample size and percent of missing data had no significant effects (𝑝 = .30,
𝜂𝑝2 = .000), (𝑝 = .22, 𝜂𝑝2 = .000), respectively (Tables 5 and 6). Additionally, the
interaction term between sample size and percent of missing data was also nonsignificant
(𝑝 = .42, 𝜂𝑝2 = .000).
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Table 5
Anova Summary Table for ES = .5
Source
SZ
Miss
SZ * Miss
Error
Total

Sum of
Squares
.02
.03
.04
79.91
80.00

df
2
2
4
8991
8999

Mean
Square
.01
.01
.01
.01

F
1.21
1.51
.97

p
.300
.222
.421

Partial Eta Squared
(𝜂𝑝2 )
.000
.000
.000

Table 6
Effect Size Estimate Means of ES = .5 by Level of Sample Size
Sample Size
Small = 5
Medium = 20
Large = 50
Total

Mean
.497
.500
.500
.499

Standard Errors
Effect Size = .7. Regarding the first outcome standard error estimates, the main effects of
sample size and percent of missing data were both statistically significant and had a
meaningful partial eta squared value (𝑝 < .001, 𝜂𝑝2 = .351) and (𝑝 < .001, 𝜂𝑝2 = .082),
respectively, for the standard error of the coefficients for ES = .7 (Table 7). The two-way
interaction between sample size and percent of missing was also significant (𝑝 < .001, 𝜂𝑝2
= .022) meaning that different levels of sample size and percent of missing data had at
least a small effect on the standard errors of the UVMA coefficient estimates (Figures 2
and 3). A simple main effects analysis was conducted since interpreting the main effect in
the presence of a significant interaction might be misleading.
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Table 7
Anova Summary Table for Standard Error Estimates for ES = .7
Sum of
Squares
4.95
.82
.21

Partial Eta Squared
(𝜂𝑝2 )
df Mean Square
F
p
2
2.47
2434.70 <.001
.351
2
.41
402.30 <.001
.082
4
.05
51.24 <.001
.022

Source
SZ
Miss
SZ *
Miss
Error
9.13
8991
<.001
Total
15.10
8999
Note: SZ = Sample size (5,20,50); Miss = The percent of missing data (0.0%,30%,70%).
Figure 2
Mean Standard Error of Level of Missingness by Sample Size
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Figure 3
Mean Standard Error of Sample Size by Percent of Missing Data

Simple main effects for percent of missing data by sample size
Effect size = .7. There was a small effect of the main effect of percent of missing data on
standard error for ES = .7 when the sample size was small or large (p < .001, partial 𝜂𝑝2 =
.025), (p < .001, partial 𝜂𝑝2 = .027) (Table 8). However, the main effect of percent of
missing data had a moderate effect when the sample size was medium. Since this
particular simple main effect was statistically significant, the difference in mean standard
errors between percent of missing data for the three levels of sample size was considered
next. Table 9 below presents the means by cell and Table 10 presents the results of the
pairwise comparisons.
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Table 8
Simple Main Effects of Percent Missing by Sample Size for ES = .7
Sample Size
Small = 5 Contrast
Error
Medium = Contrast
20
Error
Large = 50 Contrast
Error

Sum of
Squares
.232
9.130
.544
9.130
.249
9.130

Mean
df Square
F
p
2
.12
114.29 <.001
8991 .00
2
.27
268.03 <.001
8991 .00
2
.12
122.46 <.001
8991 .00

Partial Eta
Squared (𝜂𝑝2 )
.025
.056
.027

In the situation when 30% and 70% of data were missing and the sample size was
small, the mean standard error was .020 and 0.017, higher when 30% and 70% of data
were missing than when there were no missing data. In addition, when the sample size
was small, the mean standard error was .004, higher for 30% of data missing than for
70% of missing data.
In the case of medium sample size, when there were no missing data, the mean
standard error was .009, higher when 30% of data were missing than when there were no
missing data. The mean standard error was .032 higher when 70% of data were missing
than when there were no missing data. Additionally, when the sample size was medium,
the mean standard error was .023, higher when 70% of data were missing than for 30% of
missing data. For large sample sizes and when there were no missing data, the mean
standard error was .006, higher when 30% of data were missing than when there were no
missing data. When there was 70% of missingness, the mean standard error was .022,
higher when 70% of data were missing than for 30% of missingness. The mean standard
error was .016, higher when 70% of data were missing than when 30% of data were
missing.
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Table 9
Descriptive statistics for sample size as a function of percent of missing data
Sample Size
Small = 5

Percent of Missing Data
Mean
SD
No Missing data
.082
.034
30% missing data
.103
.056
70% missing data
.099
.063
Total
.095
.053
Medium = 20 No Missing data
.045
.007
30% missing data
.054
.011
70% missing data
.077
.026
Total
.058
.022
Large = 50
No Missing data
.029
.003
30% missing data
.035
.004
70% missing data
.050
.006
Total
.038
.010
Total
No Missing data
.052
.030
30% missing data
.064
.044
70% missing data
.075
.044
Total
.064
.041
Note: N represents the sample size of the particular level of missingness

N
1000
1000
1000
3000
1000
1000
1000
3000
1000
1000
1000
3000
3000
3000
3000
9000

Table 10
Pairwise Comparison Results
Sample
Size

(I) Percent of
Missing Data

(J) Percent of
Missing Data

Mean
Difference (I-J)

SD

p

Small = 5

No Missing data

30% missing data

-.020

.001

<.001

70% missing data

-.017

.001

<.001

30% missing data

70% missing data

.004

.001

.028

No Missing data

30% missing data

-.009

.001

<.001

70% missing data

-.032

.001

<.001

30% missing data

70% missing data

-.023

.001

<.001

No Missing data

30% missing data

-.006

.001

<.001

70% missing data

-.022

.001

<.001

70% missing data

-.016

.001

<.001

Medium =
20
Large = 50

30% missing data
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Effect size = .5. For the second outcome, the main effects of sample size on standard
error were also significant and had a large partial eta squared value (𝑝 < .001, 𝜂𝑝2 = .305).
The percent of missing data was significant and had a small to moderate effect (𝑝 < .001,
𝜂𝑝2 = .046) on the standard error (Table 11). The two-way interaction between sample size
and percent of missing data was also significant and had a larger effect on the standard
error estimate when compared to the first outcome (𝑝 < .001, 𝜂𝑝2 = .078), meaning that
different levels of sample size and percent of missing data had at least a small effect on
the value of the UVMA standard error estimates for outcome two. Since the interaction of
sample size and percent of missing data had an interpretable effect size, simple main
effects analysis was conducted (Figures 4 and 5).
Table 11
Anova Summary Table for Standard Error Estimates for ES = .5
Sum of
Mean
Partial Eta
Squared
(𝜂𝑝2 )
Source
Squares
df
Square
F
p
SZ
3.48
2
1.74
1972.10 <.001
.305
Miss
.38
2
.19
216.97 <.001
.046
SZ * Miss
.67
4
.17
190.87 <.001
.078
Error
7.94
8991
.00
Total
12.48
8999
Note. SZ = Sample size (5,20,50); Miss = The percent of missing data (0.0%,30%,70%).
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Figure 4
Mean standard error of Level of Missingness by Sample Size

Figure 5
Forest Plot for the LDL Random-Effects ModelFigure 6
Mean standard error of Level of Missingness by Sample Size

Figure 7
Mean standard error of Sample Size by Level of Missingness

Figure 8
Mean standard error of Level of Missingness by Sample SizeFigure 9
Mean standard error of Sample Size by Level of Missingness
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Simple main effects for percent of missing data by sample size
The simple main effect of percent of missing data in ES = .5 standard error was
small when the sample size was either small or large (p < .001, partial 𝜂𝑝2 = .026; p <
.001, partial 𝜂𝑝2 = .034). However, a moderate effect of the main effect of percent of
missing data was detected in coefficient two standard error when the sample size was
medium (Table 12).
Table 12
Simple Main Effects of Percent Missing by Sample Size for ES = .5
df
Sample Size
Small = 5
Contrast
Error
Medium = Contrast
20
Error
Large = 50 Contrast
Error

Sum of
Squares
.21
7.94
.57
7.94
.28
7.94

Partial Eta
Mean
Squared
(𝜂𝑝2 )
Square
F
p
2
.11 120.46 <.001
.026
8991
.00
2
.28 322.05 <.001
.067
8991
.00
2
.14 156.20 <.001
.034
8991
.00

Pairwise comparisons were carried out since the simple main effect of percent of
missing data was statistically significant. The pairwise comparisons table is presented in
(Table 13). From Table 13, when there were no missing data, the mean standard error
was .013, higher when 30% of data were missing than when there were no missing data.
In the situation when 70% of data were missing, the mean standard error was .007, higher
when no missing data were present than when there were 70% of data missing. In
addition, when the sample size was small, the mean standard error was .020, higher for
30% of data missing than for 70% of missingness.
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Table 13
Pairwise Comparisons Results
(I) Percent of
Sample Size
Missing Data
Small = 5
No Missing data

(J) Percent of
Missing Data
30% missing data
70% missing data
30% missing data 70% missing data

Mean
Difference
(I-J)
-.013*
.007*
.020*

SD
p
.001 <.001
.001 <.001
.001 <.001

Medium =
20

No Missing data

30% missing data
70% missing data
30% missing data 70% missing data

-.008*
-.032*
-.024*

.001 <.001
.001 <.001
.001 <.001

Large = 50

No Missing data

-.005*
-.022*
-.017*

.001 <.001
.001 <.001
.001 <.001

30% missing data
70% missing data
30% missing data 70% missing data

In the case of medium sample size, when there were no missing data, the mean
standard error was .008, higher when 30% of data were missing than when there were no
missing data. The mean standard error was .032 higher when 70% of data were missing
than when there were no missing data. Additionally, when the sample size was medium,
the mean standard error was .024, higher when 70% of data were missing than for 30% of
missingness.
For large sample sizes and when there was no missing data, the mean standard
error was .005, higher when 30% of data were missing than when there were no missing
data. When there was 70% missingness, the mean standard error was .022, higher when
70% of data were missing than for 30% missingness. The mean standard error was .017,
higher when 70% of data were missing than when 30% were missing. Table of means is
provided as Table 14.
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Table 14
Descriptive Statistics for Percent of Missing Data by Sample Size
Sample Size
Small = 5

Percent of Missing Data Mean
SD
No Missing data
.084
.034
30% missing data
.097
.054
70% missing data
.077
.053
Total
.086
.049
Medium = 20
No Missing data
.045
.008
30% missing data
.053
.011
70% missing data
.077
.028
Total
.059
.022
Large = 50
No Missing data
.029
.003
30% missing data
.034
.004
70% missing data
.051
.010
Total
.038
.012
Total
No Missing data
.053
.031
30% missing data
.061
.041
70% missing data
.069
.037
Total
.061
.037
Note: N is the sample size of the particular level of missingness

N
1000
1000
1000
3000
1000
1000
1000
3000
1000
1000
1000
3000
3000
3000
3000
9000

Three-way ANOVA of the MVMA Simulation
Effect Size
Effect Size = .7. As was shown previously in the two-way ANOVA of the UVMA, the
result of the three-way ANOVA of the MVMA also suggested that no interpretable
effects of sample size and percent of missing data were detected on the effect size
estimate of ES = .7 (𝑝 = .015, 𝜂𝑝2 = .000), (𝑝 =.302, 𝜂𝑝2 = .000), respectively (Table 15).
In addition to sample size and percent of missing data, between-study correlation was
added as a third independent variable in this analysis. However, the results of the
ANOVA showed that between-study correlation had no interpretable effect on the effect
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size estimate of ES = .7 (𝑝 = .96, 𝜂𝑝2 = .000). Moreover, the interaction terms, sample size
with between-study correlation, sample size with percent of missing data, between-study
correlation with percent of missing data, and the three way interaction were too small to
interpret (𝑝 = 1.00, 𝜂𝑝2 = .000), (𝑝 = .16, 𝜂𝑝2 = .000), (𝑝 = .99, 𝜂𝑝2 = .000), and (𝑝 = 1.00,
𝜂𝑝2 = .000), respectively.
Table 15
Anova Summary Table for Effect Size Coefficient Estimate for ES = .7
Partial Eta
Sum of
Mean
Squared (𝜂𝑝2 )
Source
Squares
df
Square
F
p
SZ
.03
2
.02
4.23 .015
.000
BSC
1.08E-5
1
.00
.00 .959
.000
Miss
.01
2
.00
1.20 .302
.000
SZ * BSC
5.77E-7
2
.00
.00 1.000
.000
SZ * Miss
.03
4
.01
1.63 .164
.000
BSC * Miss
6.28E-5
2
.00
.01 .992
.000
SZ * BSC * Miss
5.58E-5
4
.00
.00 1.000
.000
Error
72.88 17982
.00
Total
72.95 17999
Note: SZ = Sample size (5,20,50); BSC = Between-study correlation (0.1,0.9); Miss =
The percent of missing data (0.0%,30%,70%).
Effect Size = .5. Regarding the effect size estimate of ES = .5, the three-way ANOVA
showed that sample size, between-study correlation, and percent of missing data had no
interpretable effects (𝑝 = .10, 𝜂𝑝2 = .000), (𝑝 = .90, 𝜂𝑝2 = .000), and (𝑝 = .13, 𝜂𝑝2 = .000)
respectively (Table 16). Additionally, the interaction term between sample size and
between-study correlation, sample size and percent of missing, between-study correlation
and percent of missing data, were also too small to interpret (𝑝 = 0.99, 𝜂𝑝2 = .000; 𝑝 = .28,
𝜂𝑝2 = .000; 𝑝 = .95, 𝜂𝑝2 = .000), respectively. Finally, the three-way interaction of the three
independent variables had a negligible effect (𝑝 = .99, 𝜂𝑝2 = .000).
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Table 16
Anova Summary Table for Effect Size Coefficient Estimate for ES = .5
Sum of
Mean
Partial Eta
Squared 𝜂𝑝2
Source
Squares
df
Square
F
p
SZ
.05
2
.03
2.33 .098
.000
BSC
.00
1
.00
.01 .903
.000
Miss
.04
2
.02
2.04 .131
.000
SZ * BSC
.00
2
.00
.02 .985
.000
SZ * Miss
.05
4
.01
1.27 .280
.000
BSC * Miss
.00
2
.00
.05 .951
.000
SZ * BSC * Miss
.00
4
.00
.03 .998
.000
Error
193.95 17982
.01
Total
194.10 17999
Note: SZ = Sample size (5,20,50); BSC = Between-study correlation (0.1,0.9); Miss =
The percent of missing data (0.0%,30%,70%).
Standard Errors
Effect size = .7. The three-way ANOVA of the standard error for ES = .7 suggested that
different levels of sample size had a large effect on the standard error estimates (p < .001,
𝜂𝑝2 = .571) (Table 17). However, between-study correlation, percent of missing data, and
interaction terms were all nonsignificant and had no effect on the standard error
estimates. Mean standard error estimates for ES = .7 by levels of sample size are
presented in Table 18. Scheffé’s post-hoc test was conducted to find out which pairs of
means were significantly different. The results of the tests are presented in Table 19.
The Scheffé post hoc test for significance indicated that the average standard error
was significantly lower when the sample size was large (M = .029, SD =.003) than when
the sample size was either small or medium (M = .084, SD = .033), (M = .045, SD =
.008) (p = <.001) and was significantly lower for medium than for small sample sizes.
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Table 17
Anova Summary Table for Standard Error Estimates for ES = .7
Source
SZ

Sum of
Squares
9.47

df
2

Mean
Square
4.74

F
11956.7
2
.15
2.34
.05
1.59
.02
.02

p
<.00
1
.703
.097
.947
.174
.979
.999

Partial Eta
Squared 𝜂𝑝2
.571

BSC
.00
1
5.77E-5
.000
Miss
.00
2
.00
.000
SZ * BSC
.00
2
2.14E-5
.000
SZ * Miss
.00
4
.00
.000
BSC * Miss
.00
2
8.41E-6
.000
SZ * BSC * Miss
.00
4
7.79E-6
.000
Error
7.12
17982
.00
Corrected Total
16.60
17999
Note: SZ = Sample size (5,20,50); BSC = Between-study correlation (0.1,0.9); Miss =
The percent of missing data (0.0%,30%,70%).
Table 18
Standard Error Mean Estimate for ES = .7 by Level of Sample Size
Sample Size
Small = 5
Medium = 20
Large = 50
Total

Mean Std. Deviation
.084
.033
.045
.008
.029
.003
.052
.030

Table 19
Scheffé’s Comparison for Standard Error Mean Estimate for ES = .7

(I) Sample Size
Small = 5
Medium = 20

Mean Difference
(I-J)
.039
.055
.016

(J) Sample Size
Medium = 20
Large = 50
Large = 50

SD

Sig.
.000 <.001
.000 <.001
.000 <.001

Effect size = .5. The three-way ANOVA of the standard error for ES = .5 showed
interpretable main effects for sample size and percent missing but not for between-study
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correlation. Further, there was a statistically significant interaction between sample size
and percent missing (Table 21). Figure 7 displays the interaction. No other interactions
were significant. Simple main effects were then conducted due to the significant
interaction.
Table 20
Descriptive statistics for Percent of Missing Data by Sample Size for ES = .5
Sample Size
Small = 5
Medium = 20
Large = 50
Total

Mean
.088
.057
.037
.061

SD
.048
.021
.011
.037

N
6000
6000
6000
18000

Table 21
Anova Summary Table for Standard Error Estimates for ES = .5
Partial Eta
Sum of
Mean
Squared
𝜂𝑝2
Source
Squares
df
Square
F
p
SZ
7.76
2
3.88
4368.59 <.001
.327
BSC
.00
1
.00
.12
.728
.000
Miss
.82
2
.41
461.81 <.001
.049
SZ * BSC
.00
2
.00
.03
.967
.000
SZ * Miss
.56
4
.14
157.12 <.001
.034
BSC * Miss
.00
2
.00
.02
.977
.000
SZ * BSC * Miss
.00
4
.00
.17
.953
.000
Error
15.98
17982
.00
Total
25.13
17999
Note: SZ = Sample size (5,20,50); BSC = Between-study correlation (0.1,0.9); Miss =
The percent of missing data (0.0%,30%,70%).
Simple main effects for percent of missing data by sample size
In the situation where the sample size was either small or large, the effect of
simple main effect of percent of missing data in coefficient two standard error was small
(p < .001, partial 𝜂𝑝2 = .007), (p < .001, partial 𝜂𝑝2 = .029) (Table 22). However, a
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moderate main effect of percent of missing data was detected in coefficient two standard
error when the sample size was medium (p < .001, partial 𝜂𝑝2 = .046).
Table 22
Simple Main Effects of Percent Missing by Sample Size for ES = .5
Sum of
Sample Size
Squares
df
Small = 5 Contrast
.12
2
Error
15.98 17982
Medium = Contrast
.78
2
20
Error
15.98 17982
Large = 50 Contrast
.48
2
Error
15.98 17982

Mean
Square
F
p
.06 67.41 <.001
.00
.39 437.14 <.001
.00
.24 271.50 <.001
.00

Partial Eta
Squared 𝜂𝑝2
.007
.046
.029

Since the simple main effects were all significant, pairwise comparisons were
carried out. Table 23 below presents the pairwise comparisons and Table 24 provides the
cell means and standard deviations. Results for small sample size were significant but
with an effect too small to be interpretable but are presented below for completeness.
According to Table 23, when the sample size was small, the mean standard error was
.010, higher when 30% of data were missing than when there were no missing data. In
the situation when 70% of data were missing, the mean coefficient two standard error
was .002, higher when no missing data were present of than when there was 70% of data
missing. In addition, when the sample size was small, the mean ES = .5 standard error
was .009, higher for 30% of data missing than for 70% of missingness.
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Table 23
Pairwise Comparison Results for ES = .5
(I) Percentage of (J) Percentage of
Mean
Sample Size Missingness
Missingness
Difference (I-J)
Small = 5
No Missing data 30% missing data
-.010*
70% missing data
-.002
30% missing data 70% missing data
.009*
Medium = 20 No Missing data 30% missing data
-.007*
70% missing data
-.027*
30% missing data 70% missing data
-.020*
Large = 50
No Missing data 30% missing data
-.005*
70% missing data
-.021*
30% missing data 70% missing data
-.016*

SD
.00
.00
.00
.00
.00
.00
.00
.00
.00

p
<.001
.290
<.001
<.001
<.001
<.001
<.001
<.001
<.001

Table 24
Descriptive Statistics for Percent of Missing Data by Sample Size
Sample Size
Small = 5

Medium = 20

Large = 50

Total

Percentage of Missingness
No Missing data
30% missing data
70% missing data
Total
No Missing data
30% missing data
70% missing data
Total
No Missing data
30% missing data
70% missing data
Total
No Missing data
30% missing data
70% missing data
Total

Mean
.084
.094
.086
.088
.045
.052
.072
.057
.029
.034
.050
.037
.053
.060
.069
.061

Note: N is the sample size of the particular level of missingness
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SD
.033
.054
.054
.048
.008
.011
.027
.021
.003
.004
.010
.011
.030
.040
.039
.037

N
2000
2000
2000
6000
2000
2000
2000
6000
2000
2000
2000
6000
6000
6000
6000
18000

For medium sample size, when there were no missing data, the mean ES = .5
standard error was .007, higher when 30% of data were missing than when there was no
missing data. The mean ES = .5 standard error was .027 higher when 70% of data were
missing than when there were no missing data. Moreover, when the sample size was
medium, the mean ES = .5 standard error was .020, higher when 70% of data were
missing than for 30% of missingness.
For large sample sizes and when there was no missing data, the mean ES = .5
standard error was .005, higher when 30% of data were missing than when there was no
missing data. In the case of 70% of data missing, the mean ES = .5 standard error was
.021, higher when 70% of data were missing than for 30% of missingness. The mean ES
= .5 standard error was .016, higher when 70% of data were missing than with 30% of
missingness.
Three-Way MANOVA for Effect Size outcomes ES = .7 and ES = .5
A three-way MANOVA with two dependent variables (ES = .7 and ES = .5) and
three independent variables (method x sample size x percent of missingness) was
performed to gain a meaningful comparison between the two methods. MANOVA was
used primarily to determine whether the mean values for ES = .7 and ES = .5 outcomes
differed between the two methods. The effects of sample size and percent missingness
were also noted. As seen above, the between-studies factor had no interpretable effects in
any of the ANOVAs. The multivariate test statistic, Wilks' Lambda (Λ), is the most
widely used multivariate test statistic and was used in this test (Bray et al., 1985). Box’s
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M test of homogeneity of variance-covariance matrices was evaluated before interpreting
the MANOVA results.
As in ANOVA, partial eta squared (𝜂𝑝2 ) rules of thumb for small =.01, medium
=.06, and large =.14 were used to interpret the main effects and interactions. The Box’s
M test result is displayed in Table 25. Box’s M suggested that the assumption of
homogeneity of variances and covariances was violated. However, since the sample sizes
were equal, this test result is not crucial because the MANOVA test statistic in this case
is robust to violations of the assumption of homogeneity of variance and covariance
matrices (Field & Miles, 2010).
Table 25
Box's Test of Equality of Variance/Covariance Matrices
Box's M
F
df1
df2
p

24418.13
478.42
51.00
424543627.78
<.001

The multivariate test of ES = .7 and ES = .5 showed that there was no significant
effect of percent of missing data and method on the effect size estimates for ES = .7 and
ES = .5 (Table 26). Sample size was significant, but it had a negligible partial eta square
(p = .039, partial 𝜂𝑝2 = .000). Furthermore, the two-way and three-way interactions were
also nonsignificant. Next, a multivariate test was conducted for standard error. Table 27
shows Box’ M test result which again suggested that homogeneity of variance/covariance
matrices cannot be assumed. The MANOVA revealed that sample size had a large effect
on the standard error estimates of ES = .7 and ES = .5 (p <.001, partial 𝜂𝑝2 = .335).
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Percent of missing data and method were also significant, p <.001, partial 𝜂𝑝2 = .041, and
p <.001, partial 𝜂𝑝2 = .043, respectively, and had a small effect (Table 28).
Table 26
Manova Summary Table for the Effect Size Estimate

Effect
SZ
Miss
Method
SZ * Miss
SZ * Method
Miss * Method
SZ * Miss *
Method

Value F
1.00 2.52
1.00 1.80
1.00 .89
1.00 1.77
1.00 .14
1.00 .72
1.00 .19

df
4.00
4.00
2.00
8.00
4.00
4.00
8.00

Error df
35962.00
35962.00
17981.00
35962.00
35962.00
35962.00
35962.00

p
.039
.127
.412
.077
.967
.578
.992

Partial Eta Squared
𝜂𝑝2
.000
.000
.000
.000
.000
.000
.000

Table 27
Box's Test of Equality of Variance/Covariance Matrices
Box’s M
F
df1
df2
p

56519.83
1107.39
51.00
424543627.78
<.001

Table 28
Manova Summary Table for the Standard Error Estimate
Effect
SZ
Miss
Method
Method * SZ
Method * Miss
SZ * Miss
Method * SZ *
Miss

Value
.44
.92
.96
1.00
.97
.94
.99

F
4536.92
382.79
408.07
8.96
137.44
147.12
26.78

df
4.00
4.00
2.00
4.00
4.00
8.00
8.00

Error df
35962.00
35962.00
17981.00
35962.00
35962.00
35962.00
35962.00
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p
<.001
<.001
<.001
<.001
<.001
<.001
<.001

Partial Eta Squared
𝜂𝑝2
.335
.041
.043
.001
.015
.032
.006

Since multivariate significance was detected, univariate ANOVA results are
presented and interpreted next as a follow up to MANOVA to identify any significant
group differences for each of the effect sizes (.7 and .5).
The ANOVA revealed that the difference by method was only significant for ES
= .7, with a small effect, (p <.001, partial 𝜂𝑝2 = .043) (Table 29). Sample size differences
were also significant for both ES = .7 and ES = .5 and had a large effect (p <.001, partial
𝜂𝑝2 = .433) and (p <.001, partial 𝜂𝑝2 = .324), respectively. The percent of missing data
was found to be significant with a small effect on the standard error estimates for ES = .7
and ES = .5 (p <.001, partial 𝜂𝑝2 = .033) and (p <.001, partial 𝜂𝑝2 = .049), respectively.
Even though the interaction effect of method and sample size was found to be statistically
significant for standard error estimates, the value of 𝜂𝑝2 was very small and ignorable (p
<.001, partial 𝜂𝑝2 = .001) and (p <.001, partial 𝜂𝑝2 = .001), respectively. The method by
sample size two-way interaction was only significant with a small effect on ES = .7)
standard error estimates (p <.001, partial 𝜂𝑝2 = .030). The last two-way interaction
between sample size and percent of missing data was significant and had a moderate
effect for ES = .5 standard error estimates (p <.001, partial 𝜂𝑝2 = .055). However, sample
size and percent of missingness interaction had an ignorable effect on ES = .7 standard
error estimates. Finally, the three way- interaction between method, sample size, and
percent of missingness was found to have an ignorable effect on both ESs standard error
estimates.
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Table 29
Univariate Anova Summary
Dependent Sum of
Source
Variable
Squares
Method
(ES = .7)
.57
SE = .5)
(ES
.00
SE = .7)
SZ
(ES
9.65
SE = .5)
(ES
7.36
SE
Miss
(ES = .7)
.43
SE = .5)
(ES
.79
SE = .7)
Method * SZ
(ES
.01
SE = .5)
(ES
.01
SE
Method * Miss (ES = .7)
.39
SE
(ES = .5)
.00
SE = .7)
SZ * Miss
(ES
.10
SE = .5)
(ES
.89
SE = .7)
Method * SZ * (ES
.11
Miss
SE
(ES = .5)
.05
SE = .7)
Error
(ES
12.65
SE =. 5)
(ES
15.34
SE = .7)
Total
(ES
23.92
SE
(ES = .5)
24.44
SE

Mean
df
Square
1.00
.57
1.00
.00
2.00
4.82
2.00
3.68
2.00
.22
2.00
.40
2.00
.01
2.00
.01
2.00
.19
2.00
.00
4.00
.03
4.00
.22
4.00
.03
4.00
.01
17982.0 .00
0
17982.0
.00
0
17999.0
0
17999.0
0

F
814.85
.51
6854.4
3
4315.1
0
306.03
463.94
10.61
7.20
275.22
1.86
35.63
260.24
38.84
14.16

p
<.00
1
.474
<.00
1
<.00
1
<.00
1
<.00
1
<.00
1
<.00
1
<.00
1
.155
<.00
1
<.00
1
<.00
1
<.00
1

Partial Eta
Squared 𝜂𝑝2
.043
.000
.433
.324
.033
.049
.001
.001
.030
.000
.008
.055
.009
.003

Scheffé’s post-hoc test was performed to find out which pairs of means were
significantly different (Table 30). For ES = .7, the mean standard error was .037 and .056
higher when the sample size was small than when the sample size was medium and large,
respectively. The mean standard error was .018 higher when sample size was medium
than when it was large. Regarding ES = .5, the mean standard error was .029 and .049
higher when the sample size was small than when the sample size was medium and large,
respectively. The mean standard error was also .020 higher when the sample size was
medium than when the sample size was large.
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Table 30
Pairwise Comparison Results for ES = .7 and ES = 0.5
(J) Sample
Mean Difference
Size
(I-J)
ES = .7 SE
Medium = 20
.037
Large = 50
.056
Medium = 20
Large = 50
.018
ES = .5 SE
Small = 5
Medium = 20
.029
Large = 50
.049
Medium = 20
Large = 50
.020
Note: ES = effect size; SE = standard error; SD = standard deviation
(I) Sample Size
Small = 5

SD
.000
.000
.000
.001
.001
.001

p
<.001
<.001
<.001
<.001
<.001
<.001

Table 31
Pairwise Comparison Results for ES = .7 and ES = 0.5
Dependent
Variable
ES = .7 SE

ES = .5 SE

(I) Percentage of (J) Percentage of Mean Difference
Missingness
Missingness
(I-J)
No Missing data 30% missing data
-.006
70% missing data
-.012
30% missing data 70% missing data
-.006
No Missing data 30% missing data
-.008
70% missing data
-.016
30% missing data 70% missing data
-.008

SD
.000
.000
.000
.001
.001
.001

p
<.001
<.001
<.001
<.001
<.001
<.001

Tables 32, 33, and 34 present the mean and standard deviation of standard error
estimates by method, sample size, and percent of missing data for ES = .7 and ES = .5.
Table 32
Means and Standard Deviations for MVMA and UVMA Estimates
(ES = .7) SE
UVMA
MVMA

Mean
.064
.052

SD
.041
.030
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(ES = .5) SE
Mean
.061
.061

SD
.037
.036

Table 33
Means and Standard Deviations for MVMA and UVMA Standard Error Estimates by
Percent of Missing Data
Percent of missing data
No Missing data
Mean
SD
30% missing data
Mean
SD
70% missing data
Mean
SD

MVMA
UVMA
ES = .7 SE ES = .5 SE ES = .7 SE ES = .5 SE
.052
.053
.052
.053
.030
.030
.030
.031
.053
.060
.064
.061
.030
.040
.044
.041
.053
.069
.075
.069
.030
.036
.044
.037

Table 34
Means and Standard Deviations for MVMA and UVMA Standard Error Estimates by
Sample Size
Sample Size
Small = 5
Medium = 20
Large = 50

Mean
SD
Mean
SD
Mean
SD

MVMA
ES = .7 SE ES = .5 SE
.083
.088
.033
.046
.045
.056
.008
.021
.029
.037
.003
.011
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UVMA
ES = .7 SE ES = .5 SE
.095
.086
.053
.049
.058
.059
.022
.022
.038
.038
.010
.012

Results of the univariate and multivariate meta-analysis of CDSSs
Univariate Meta-Analysis of the Effect of CDSSs on LDL Levels
The first of three meta-analyses estimated the mean effect of CDSS’s on reducing
LDL levels in diabetic patients. A random-effects model and restricted maximum
likelihood estimation (REML) were used in the three meta-analyses. The number of
studies were included in this meta-analysis was 16 studies and a total number of 10,603
patients. The estimate of the mean effect size of CDSS’s using a random-effects model
was significant 𝑆𝑀𝐷 = -0.07, 95% 𝐶𝐼 [-0.12, -0.02]. According to Cohen’s (1988)
guidelines, defined SMD effect sizes as small (0.2), medium (0.5), and large (0.8)., the
SMD of -0.07 is considered as a very small. The estimate for 𝜏 2 , the total heterogeneity,
was 𝜏 2 = 0.001, and the estimated between-studies standard deviation 𝜏 was 𝜏 = 0.03. The
result of the test of heterogeneity was (𝑑𝑓=15) = 20.81, 𝑝 = .007, and 𝐼 2 = 12.88%.
According to Higgins and Thompson’s (2002), guidelines for interpreting the descriptive
statistic 𝐼 2 , the 𝐼 2 value of about approximately 13% for this meta-analysis indicated the
heterogeneity might not be important.
Figure 6 shows the forest plot, the estimated mean difference, and its 95%
confidence interval. The squares close to the center of the estimated mean difference will
be larger for studies with smaller variances and so more precision. The dashed vertical
line down the middle represents the line of no effect. Each square has a horizontal line
extending through it that represents the study’s 95% confidence interval. The shorter the
line, the more precise the estimate of that study’s effect size (Borenstein et al., 2011;
Card, 2015). The black diamond on the summary line represents two things: the center of
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this black diamond represents the mean effect size for this sample of studies and its width
indicates the 95% confidence interval for the mean effect size.
Publication Bias
The funnel plot is usually used to assess bias in a meta-analysis (Ferrer, 1998;
Song et al., 2002; Tang & Liu, 2000). Therefore, the first step was to generate a funnel
plot in order to get an initial understanding of the risk of bias if present. In this plot, the
y-axis represents the standard error and the x-axis represents the effect size. Each dot
represents a study. If publication bias is present, the funnel plot will be asymmetrical.
Figure 7 shows the funnel plot of the studies included and as it appears from the plot, no
evidence of bias is detected as the dots seem to be randomly scattered around the funnel.
In order to discover the number of missing studies that would lead the overall effect to a
non-zero level, the Fail-safe N method was used. The result of Fail-safe N indicated that
17 studies with effect size zero could be added to the meta-analysis before the result lost
statistical significance. However, looking at the forest plot in figure 8, there are only three
studies that do not include the line of no effect. Therefore, it might not be difficult to get
17 studies. Finally, and as a way to visualize the studies that might be missing, a Trim and
Fill algorithm was used and then the funnel plot in Figure 8 was generated.
The hollow dots indicate studies that need to be added in order to have a more
symmetric plot. AS shown in Figure 10, only one study was added to the funnel plot
which is evidence that the risk of publication bias was low if not present at all.
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Figure 10
Forest Plot for the LDL Random-Effects Model

Figure 11
Funnel Plot for LDL Random-Effects Model

Figure 12
Funnel Plot for LDL Random-Effects Model

Figure 13
Funnel Plot for LDL after Trim & Fill Random-Effects ModelFigure 14
Forest Plot for the LDL Random-Effects Model

81

Figure 15
Funnel Plot for LDL after Trim & Fill Random-Effects Model

Figure 16
Funnel Plot for LDL Random-Effects ModelFigure 17
Funnel Plot for LDL after Trim & Fill Random-Effects Model

Univariate Meta-Analysis of the Effect of CDSSs on HbA1c levels
The number of studies included in this meta-analysis was 38 studies with a total
number of 18,144 patients. The estimate of the mean effect size pf CDSS’s using a
random-effects model was statistically significant 𝑆𝑀𝐷 = -0.31, 95% 𝐶𝐼 [-0.48, -0.13].
SMD of -0.31 for the effect of CDSSs on the level of HbA1is considered as a small effect
size. The estimate for 𝜏 2 , the total heterogeneity, was 𝜏 2 = 0.26, and the estimated
between-studies standard deviation 𝜏 was 𝜏 = 0.51. The result of the test of heterogeneity
was 𝑄 (𝑑𝑓= 37) = 1774.13, 𝑝 < .001, and 𝐼 2 = 96.28%. The 𝐼 2 value of about
approximately 96% indicated considerable heterogeneity. Figure 9 shows the forest plot
for the HbA1c random-effects model.
Publication Bias
The funnel plot presented in Figure 10 shows the funnel plot of the 38 studies
included. It appears from the plot that some degree of asymmetry is present. There were
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some studies that have very strong effect that appear as outliers on the left and right side
of the funnel. Most of the effect sizes are scattered around the mean effect size.
Additionally, studies with small or non-significant effects might be missed as the lower
base of the funnel plot had almost no studies.
Since significant heterogeneity was detected and a random effects model was
used, Fail Safe 𝑁 was not reported per Card’s (2015) recommendation. This is because
the computation of File Safe N does take into account whether the studies are
homogeneous or heterogeneous, which makes the method invalid, especially when the
heterogeneity is large (Card, 2015). Figure 11 shows the Funnel Plot for HbA1c after a
trim and fill random-effects model was generated. The plot is identical to the original funnel
plot meaning that the meta-analysis of the HbA1c is robust to publication bias.
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Figure 18
Forest Plot for the HbA1c Random-Effects Model
Figure 19
Mean standard error of Sample Size by Level of MissingnessFigure 20
Forest Plot for the HbA1c Random-Effects Model
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Figure 23
Funnel Plot for HbA1c Random-Effects Model

Figure 24
Funnel Plot for PP Random-Effects ModelFigure 25
Funnel Plot for HbA1c after Trim & Fill Random-Effects Model

Figure 21
Funnel Plot for HbA1c after Trim & Fill Random-Effects Model
Figure 22
Funnel Plot for HbA1c Random-Effects Model
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Univariate Meta-Analysis of the Effect of CDSSs on Blood Pressure levels
The third UVMA was the meta-analysis of the effect of CDSSs on blood pressure
levels. As mentioned in Chapter 2, the outcome of blood pressure was converted to Pulse
Pressure (PP) in order to have only one value that represents blood pressure level. The
number of studies included in this meta-analysis was 20 studies and a total number of
11,841 patients. The estimate of the mean effect size was non-significant 𝑆𝑀𝐷 = -0.55,
95% 𝐶𝐼 [-1.24, 0.15]. The estimate for 𝜏 2 , the total heterogeneity, was 𝜏 2 = 2.48, and the
estimated between-studies standard deviation 𝜏 was 𝜏 = 1.58. The result of the test of
heterogeneity was 𝑄 (𝑑𝑓= 19) = 7950.36, 𝑝 < .001, and 𝐼 2 = 99.47%. According to the
value of 𝐼 2 , a considerable heterogeneity is present. Figure 12 shows the forest plot for
the pulse pressure random-effects model.
Publication Bias
A funnel plot was created for the 20 studies included in the analysis (Figure 13). It
can be seen from the plot that a large amount of heterogeneity is present from the spread
of the studies. There were some studies that had a very strong effect on the left side of the
funnel. Studies with small or non-significant effects could be missed at the lower base of
the funnel plot as well as the top left.
Again, Fail Safe 𝑁 was not reported per Card’s (2015) recommendation because
of the significant heterogeneity. Figure 14 shows the funnel plot for PP after a trim and fill
random-effects model was generated which indicated that 5 studies could be missed on the
right side of the funnel which is an indication of publication bias.

86

Figure 26
Forest Plot for PP Random-Effects Model

Figure 27
Forest Plot for PP Random-Effects ModelFigure 28
Funnel Plot for PP Random-Effects Model

Figure 29
Funnel Plot for PP Random-Effects Model

Figure 30
Funnel Plot for PP after Trim & Fill Random-Effects ModelFigure 31
Forest Plot for PP Random-Effects Model
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Figure 32
Funnel Plot for PP after Trim & Fill Random-Effects Model

Figure 33
Funnel Plot for LDL, HbA1c, and PP Random-Effects ModelFigure 34
Funnel Plot for PP after Trim & Fill Random-Effects Model

Multivariate Meta-Analysis for the Effect of CDSSs on the levels of LDL, HbA1C,
and PP
Two multivariate meta-analyses of 41 studies were conducted in order to assess
the effect of the CDSSs on the three outcomes under study. The first MVMA was
conducted with missing cells deleted which contained no information about the particular
outcome. The second MVMA was conducted with missing values imputed, assuming that
they were missing completely at random. The result of both MVMAs are presented next.
MVMA with Missing Values Deleted
In this MVMA, the result shows that the estimated effect size of the CDSSs for all
of the three outcomes was less than small, LDL = -0.10, 95% 𝐶𝐼 [-0.61, 0.41], HbA1c = 0.27, 95% 𝐶𝐼 [-0.53, -0.01] and PP = -0.26, 95% 𝐶𝐼 [-0.62, 0.11]. ). However, CDSSs had
a significant and less than small effect on HbA1c levels. The estimate for 𝜏 2 , the total
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heterogeneity, was 𝜏 2 = 0.58, and the estimated between-studies standard deviation 𝜏 was
𝜏 = 0.76. The result of the test of heterogeneity was 𝑄 (𝑑𝑓= 67) = 44480.55, 𝑝 < .001
meaning that heterogeneity was present.
Publication Bias
The funnel plot of the three outcomes shows that some degree of asymmetry
might be present (Figure 17). It appears from the plot that there might be some studies
that are missing on the left (upper and lower) sides of the funnel. To find out how many
studies are missing, a trim and fill approach was used. However, the use of the trim and fill
approach is slightly different in MVMA. In order to run a trim and fill random effects model,
the function “rma” was used instead of “rma.mv” since the latter does not support trim and
fill for MVMA. The result of the trim and fill approach showed that there were 21 missing
studies for the funnel plot to be symmetric. Figure 17 shows the funnel plot after trim and fill.
It should be mentioned that in Figure 16 and Figure 17, the standard errors were plotted

Figure 35
Funnel Plot for LDL, HbA1c, and PP Random-Effects Model
Figure 36
Figure 37
Funnel Plot for LDL, HbA1c, and PP Random-Effects Model
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against the observed values instead of the residuals in order to run the trim and fill analysis
for MVMA.

MVMA with Missing Values Imputed
In this MVMA, instead of deleting the cells that had missing values, the MICE
Package (Multivariate Imputation via Chained Equations) was used (Buuren, S. V., &
Groothuis-Oudshoorn, K, 2010). MICE is one of the commonly used packages for R
users (Z. Zhang, 2016). The result of this MVMA showed that the estimated effect size
for the three outcomes were , LDL = -0.19, 95% 𝐶𝐼 [-0.39,0.00], HbA1c = -0.21, 95% 𝐶𝐼
[-0.43, -0.01] and PP = -0.19, 95% 𝐶𝐼 [-0.37, -0.01]. ). CDSSs had a significant effect on
the levels of HbA1c and PP. CDSSs had a small effect on HbA1c, and a less than small
effect on PP. The estimate for 𝜏 2 , the total heterogeneity, was 𝜏 2 = 0.43, and the estimated
between-studies standard deviation 𝜏 was 𝜏 = 0.65. The result of the test of heterogeneity
was 𝑄 (𝑑𝑓= 120) = 65478.70, 𝑝 < .001 indicating that heterogeneity was present.
Publication Bias
The funnel plot of LDL, HbA1c, and PP shows that there is still some degree of
asymmetry (Figure 18). It can be seen from the funnel plot in Figure 18 that there might
be some missing studies on the left (upper and lower) sides of the funnel. The result of the
trim and fill approach showed that 36 studies should be added to the funnel plot to be
symmetric. Figure 19 shows the funnel plot after trim and fill.
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Figure 39
Funnel Plot for LDL, HbA1c, and PP Random-Effects Model

Figure 40
Funnel Plot for HbA1c Random-Effects ModelFigure 41
Funnel Plot for LDL, HbA1c, and PP Random-Effects Model

Figure 38
Funnel Plot for LDL, HbA1c, and PP After Trim & Fill Random-Effects Model
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The results of the three UVMAs and the two MVMAs are summarized in Table
35.
Table 35
Summary of the result of the two MVMAs
Outcome

UVMA

MVMA
Imputed missing values
ES
SE
95% CI

MVMA
Deleted missing values
ES
SE
95% CI

ES

SE

95% CI

LDL

-0.07

0.03

-0.12 - -0.02

-0.19

0.10

-0.39 - 0.00

-0.10

0.26

-0.61 - +0.41

HbA1c

-0.31

0.09

-0.48 - -0.13

-0.21

0.11

-0.43 - -0.01

-0.27

0.13

-0.53 - -0.01

PP

-0.55

0.35

-1.24 - +0.15

-0.19

0.09

-0.37 - -0.01

-0.26

0.18

-0.62 - +0.11

The aim of this dissertation was twofold. First, simulations were conducted to
understand whether sample size, percent of missing data, and between-study correlation
had an effect on meta-analysis estimates. Secondly, an empirical study was conducted to
evaluate the effect of CDSSs on diabetes management. The idea of conducting these two
studies was to first understand what effect the factors would have on the two outcomes
(ES = .7 and ES = .5) and then compare the findings with the results of the empirical
study of the CDSSs. However, several factors affected this comparison with the empirical
study. The simulations had two outcomes while the empirical study had three. In the
empirical study, due to the lack of information reported in the selected studies, several
imputations were conducted in the MVMA in order to estimate the variance-covariance
matrix and the missing values. As a result of these imputations, MVMA estimates was
slightly affected. Thus, no direct comparisons between the simulation and the empirical
study were sound.
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Chapter Four
Discussion
This chapter summarizes the primary findings with links to the literature and
concludes with a review of the study limitations and recommendations for future study.
Summary of the Primary Findings of the Simulation Study
To get an initial understanding of what impact the three factors (sample size,
percent of missing data, and between-study correlation) had on both UVMA and MVMA
methods, two-way ANOVAs and three-way ANOVAs were conducted in order to
evaluate the impact of these factors on the UVMA effect size and standard error
estimates. The between-study correlation was not included in this the UVMA analysis
since a between-study correlation does not exist in the case of UVMA. This exclusion
was because the between-study correlation showed no impact on the effect size
estimation and their standard errors. Subsequently 3-way MANOVAs were used that
included method (UVMA/MVMA) as a factor in addition to sample size and percent of
missing data to directly compare the effects of method and its interaction with the other
two factors. In this subsequent analysis, ES = .7 and ES = .5 were treated simultaneously
as the dependent variables.
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ES = .7. The two-way ANOVA of the UVMA simulation found that there was no
interpretable main or interactive effect of sample size and percent of missingness on the
effect size estimate. However, the analysis showed that different levels of these factors
might have an impact on the quality of the effect size estimates (standard errors). The
influence of the percent of missingness in general was moderate. However, different
levels of sample size were found to have a large impact on the standard error estimates
for ES= .7. The effect of the percent of missingness on the ES = .7 standard error estimate
was small when the sample size was either small or large and this effect was moderate
when sample size was medium. The interaction effect of sample size and percent of
missingness was in general small. To summarize, standard errors were lower when there
were no missing data and were incrementally larger when there were higher levels of
missing data. The effect was most pronounced for small samples sizes and differences
were smaller for large sample sizes. This result can be understood as the influence of
sample size on any standard error estimate: as sample size increases, the standard error
decreases.
ES = .5. Again, the two-way ANOVA of the UVMA simulation yielded no
significant main or interactive effect of sample size and percent of missingness on the
effect size estimate. However, sample size again played a role in the estimation of the
standard errors. The analysis showed that sample size had a large effect in estimating the
standard errors. Moreover, percent of missing data was found to have a moderate effect as
in the case of ES = .7. The only difference was in the joint effect of sample size and
percent of missingness. The interaction of these two factors was moderate which is
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different than for ES = .7. The effect of missingness was small in the case of small and
large sample size. Percent of missing data showed a moderate effect when the sample size
was medium. However, as in the case of ES =.7, the difference in standard error estimates
tends to increase as the percent of missing data increases in both the medium and large
sample size.
It should be noted that results showed that 30% of missing data across the three
levels of sample size had a small difference when compared to the situation when no
missing data was present. Therefore, according to this finding, researchers should not be
overly concerned as long as the percent of missing data is 30% or less in order to get
effect size estimates that have almost the quality (small standard errors) of the estimates
that would be produced if no missing data were present.
Regarding MVMA, the ANOVA had one more factor added which was the
between-study correlation. The analysis yielded essentially the same results as the twoway ANOVA of the UVMA in case of sample size and percent of missing data for the two
effect size estimates (ES = .7 and ES = .5). No interpretable effects of these factors were
detected. In addition, there was no interpretable effect of the between study-correlation,
which supports the findings of previous literature that examined the effect of the
between-study correlation and whether it makes a difference in estimating the effect size
compared to UVMA (Boca et al., 2017; Price et al., 2019). The two- and three-way
interactions were both too small to be interpretable and had little effect on the effect size
estimates.
On the other hand, the sample size had a large effect on the estimate of the
standard error for ES = .7. The results showed that the standard error estimates decreased
95

as the sample size increased, which was to be expected. Larger sample sizes increase
precision and produce smaller standard errors for estimates (Seaman et al., 1999). The
analysis also showed that the percent of missing data had little influence on the standard
error estimates of ES = .7. In MVMA, the study does not have to have all the outcomes of
interest to be included in the analysis. One outcome is enough for a study to be included
and that inclusion reduces the effect of missing information. That is considered as an
advantage of MVMA over UVMA. The between study correlation effect again was too
small to be interpretable and had no effect on standard errors estimates of ES = .7. All
interaction terms had no interpretable effects as well.
The situation when ES = .5 was somewhat different. The effect of sample size was
still large, but it was smaller than in the case of ES = .7. The effect of percent of missing
data was interpretable, though with a small effect on the standard error of ES = .5.
Recalling the effect of missingness on the standard error estimates of the ES’s in the case
of UVMA, percent of missing data had an interpretable effect on both estimates, not only
on the one that had missing data. Including studies that have at least one of the estimates
under study allowed the MVMA to reduce this effect of missingness and hence keep
more information in order to get a better estimate with better statistical properties. The
interaction of sample size with percent of missing data was interpretable with a small
effect.
The two-way ANOVA of the UVMA and the three-way ANOVA of the MVMA
revealed some of the differences between the two methods. In UVMA, the idea of
excluding all studies that do not have all the outcomes of interest had an effect on the
standard error estimates of all effect sizes. On the other hand, in MVMA, the outcome
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with missing data was the only outcome affected by the missingness. Therefore, using
MVMA might reduce the risk of the missingness and hence produce estimates with better
statistical quality.
In order to better understand these differences, establish a more accurate
conclusion, and gain a meaningful comparison, a MANOVA was conducted which
allowed the researcher to analyze the effects of both methods simultaneously. Conducting
the MANOVA allowed inclusion of two dependent variables, ES = .7 and ES = .5, and
three independent variables (method x sample size x percent of missingness). The
between-study correlation was excluded from the analysis since it showed no impact on
the effect size estimation and their standard errors. The method factor was added which
had two levels (UVMA and MVMA) in order to see if the use of the method would have
an effect on the estimates. The multivariate analysis of ES = .7 and ES = .5 showed that
no interpretable effect was detected from method, sample size, and percent of missing
data on effect size estimates which supports the conclusions previously gained from the
ANOVAs.
The MANOVA for ES =.7 and ES = .5 standard error estimates showed that
sample size had a great effect in estimating the standard errors. Again, as sample size gets
larger, the standard errors get smaller and the estimates of ES = .7 and ES = .5 get closer
to the true values.
The MANOVA also showed that standard error estimates were slightly affected by the
percent of missing data. The type of method used, either UVMA or MVMA, was found to
have a small effect in general. An ANOVA was essential to conduct as a follow up to
identify any significant group differences for each of the effect sizes (.7 and .5).
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For the method factor, the ANOVA showed that using UVMA or MVMA might
give a different result in the case of ES = .7. The mean standard errors of MVMA were
smaller compared to UVMA in the case of ES = .7. Using UVMA when there were
missing studies resulted in standard error inflation for both ES’s (ES = .5 and ES = .7)
which is a result of excluding the studies that did not have enough data. However, mean
standard error estimates for ES = .5 were almost identical for both methods (Table 32).
Having missing data in ES = .5 was again interpretable with a small effect. In the
case of no missing data, both mean standard error estimates produced by UVMA and
MVMA were almost identical. However, mean standard error estimates of ES = .7 that
were produced by MVMA were smaller than the ones produced by UVMA with 30% and
70% of missingness with ES = .5.
MVMA was also superior to UVMA in the three levels of sample size for ES = .7.
Throughout the three levels of sample size, mean standard error estimates of ES = .7 were
smaller than the ones from the UVMA. However, mean standard error estimates of ES
= .5 were almost identical for both methods.
As a summary of the results of the simulation, between-study correlation showed
no significant effect on estimates when it was considered in MVMA simulation. This
result has been supported by the literature and still there is no clear explanation for why
between-study correlation shows no effect (D.-G. D. Chen & Peace, 2013; Price et al.,
2019). Between-study correlation might be meaningful if the studies that would be
included in a meta-analysis contain related data. That means different studies might be
included that have the same set of patients and/or same characteristics. In this case,
considering individual patient data (IPD) would be meaningful. IPD from completed
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clinical trials are usually unavailable. However, IPD should be responsibly shared in
order to enhance the reliability and efficiency of any comparative meta-analyses (Tudur
Smith et al., 2015).
MVMA performed better compared to UVMA when missing data were present. In
UVMA, all outcomes of interest would be affected by missing data and would result in
estimates with less statistical quality. Therefore, MVMA is more robust to missing data
and should be preferred over UVMA in this case. However, when no missing data are
present, both methods performed equally and the researcher should choose the most
convenient method for his/her study. Increasing the sample size was effective in reducing
the standard errors of the estimates in both methods with preference to MVMA. The more
studies included in a meta-analysis, the more information about the variables under study
will be gained. MVMA offers an easier way to reach a bigger sample size compared to
UVMA. As explained before, in UVMA the possibility of a study to be included when
there is more than one outcome of interest is low compared to MVMA where only one
outcome present in the study is enough for the study to be included (Jackson et al., 2011).
Summary of the Finding of the Univariate Meta-Analyses of Effects of CDSS
In order to evaluate the effect of CDSSs on the management of LDL, HbA1c, and
PP levels in diabetic patients, three UVMAs were conducted separately. The first UVMA
of 16 studies was conducted to evaluate the effect of CDSSs on LDL levels. The result
showed that CDSSs had a significant effect that was less than small on managing LDL
levels. This result concurs with some RCT’s and systematic reviews found that showed
the effect of the CDSSs were very small or not effective at all in managing LDL levels
(Ali et al., 2016; P. J. O’Connor et al., 2011). The measures of heterogeneity (Q and 𝐼 2 )
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both indicated heterogeneity was very small and could be ignored. Based on that result,
the studies that were included in this meta-analysis shared the same true effect size. This
claim could be supported by looking at the forest plot (Figure 8), where it can be seen
that the effect did not vary much across studies and hence the pooled effect size should be
a good reflection of the true effect size. Regarding publication bias, the funnel plot of the
studies presented in Figure 9 showed a symmetric spread of the studies which is a sign of
unbiasedness. Fail-safe N revealed that a total of 17 studies with zero effect size could be
added before the result lost statistical significance. However, as mentioned before, there
were only three studies that do not include the line of no effect meaning that 17 studies
wouldn’t be difficult to get. Finally, Trim and Fill algorithm indicated that only one study
needs to be added to the meta-analysis which again support what the funnel plot showed
(Figure 10).
The second UVMA was to examine the effect of CDSSs on managing the levels
of HbA1c. In this random-effects meta-analysis, 38 studies were included. The effect of
CDSSs was significant and had a small effect in reducing the levels of HbA1c. The
literature reported inconsistent results of the effect of CDSS in reducing levels of HbA1c.
Some reported non-significant effects and others reported small to moderate effects (Ali
et al., 2016; Jeffery et al., 2013). A high amount of heterogeneity was found based on the
values of (Q and 𝐼 2 ) meaning that there were differences in sample characteristics of the
studies. For instance, and from a clinical standpoint, while one study could have included
old people, other studies have recruited young participants. Another factor that could be a
reason behind the heterogeneity is the kind of intervention (CDSS) that was used which
varies from one study to another. Some CDSS might have a stronger effect and some
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might have small or no effect. As a result, the pooled effect size could be misleading and
not reflect the true effect size. The funnel plot of the 38 studies (Figure 12) shows that
there is a possibility of publication bias. However, as can be seen in Figure 13, the trim
and fill random-effects model Funnel plot for HbA1c is identical to the original funnel plot
which mean the little or no publication bias is present. This could be because the number of
the studies included, which is considered as a large sample size in meta-analysis, reduced the
possibility of missing related studies. Another possibility might be related to the effectiveness
of CDSSs on HbA1c levels. As mentioned earlier, and based on the literature, the effect on
HbA1c was found either non-significant or had a small to moderate effect. As a result, most
of the studies were published even with non-significant results since no large effect was
reported in the literature to the best of the researcher’s knowledge.
The last UVMA was conducted for the purpose of evaluating the effectiveness of
CDSSs on blood pressure levels which was converted during the coding process to pulse
pressure. A total of 20 studies were included in this analysis. The effect of the CDSSs on
reducing levels of PP was nonsignificant. CDSSs had been found effective in reducing blood
pressure; however, the result of the meta-analysis did not support what was found in the
literature (Ali et al., 2016; Holbrook et al., 2009; O’Connor & Sperl-Hillen, 2019). Again,
both Q and 𝐼 2 indicated that there was considerable heterogeneity. It can be noticed from

the forest plot that some studies had strong effects and some did not (Figure 14). As a
result, the pooled effect in this case was not reflective of the true effect of the CDSSs.
The funnel plot shows that some degree of publication bias was present. The right side of
the plot could be missing some studies. Based on the result of Trim and Fill, the number
of studies that are missing is 5 studies to make the funnel plot symmetric (Figure 15).
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Summary of the Results of the Multivariate Meta-Analyses of Effects of CDSS
Two MVMAs were conducted due to the fact that there were missing values. The
first MVMA was conducted with missing values deleted and an imputation technique was
used in the second MVMA instead of deleting the missing values. A total of 41 studies
were included in these MVMAs.
The first MVMA with missing values deleted yielded a nonsignificant very small
effect of CDSSs on the levels of LDL and a significant small effect on the levels of
HbA1c. the effect of CDSSs was non-significant small effect on PP. The Q test of
homogeneity indicated that heterogeneity was detected. That could be explained by the
inconsistent effect of CDSS throughout the studies. This result is different than that found
using separate UVMAs. The first thing to notice is that effect size estimates of the three
outcomes are slightly different and the effect of CDSS on PP dropped from medium to
less than small. Secondly, the standard errors of UVMA were smaller than the ones
produced by MVMA for LDL and HbA1c. However, MVMA had a smaller standard error
for the PP outcome. MVMA with missing values deleted showed that CDSSs had only a
significant effect on HbA1c. However, UVMAs yielded the finding that CDSSs had a
significant effect on LDL and HbA1c levels. Therefore, utilizing either UVMA or
MVMA could result in different conclusions. The funnel plot in Figure 16 shows some
degree of asymmetry. Studies could be missing on the top and the bottom of the left side
of the plot. Trim and Fill indicate that 21 studies missing studies would be needed for the
plot to be symmetric (Figure 17).
Deleting the missing values was one way to successfully run the R code.
However, one of the advantages of MVMA is that it can include more information about
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the outcomes. In order to see the performance of MVMA with no missing data,
imputation was applied in the second MVMA. The effect of CDSSs on LDL was still
nonsignificant. CDSSs were found to have a significant small effect on the levels of
HbA1c and a non-significant less-than small effect on PP. Heterogeneity was found to be
significant and publication bias was present with 36 studies need to be added to gain
symmetry (Figure 19).
When comparing the two MVMAs, it can be seen that MVMA with missing
values imputed had smaller standard errors for the estimates. However, effect size
estimates produced by MVMA with missing values deleted were closer to the ones
produced by the UVMAs. The three meta-analyses results were close to each other.
However, conducting three separate meta-analyses was more feasible compared to
conducting an MVMA with deleted missing values and an MVMA with imputed missing
values. MVMA appeared to be more practical to utilize when all data needed for the
analysis are provided or could be computed.
In conclusion, the results of UVMA and the two MVMAs of CDSSs’ effect on
LDL did not agree. CDSSs’ effects on LDL was found to be significant only in the
UVMA result. The conclusion was consistent in the case of HbA1c. UVMA and MVMAs
of HbA1c yielded a small effect of CDSSs on HbA1c levels. And, UVMA and MVMA
with missing data deleted agreed in which both concluded that CDSSs had a
nonsignificant effect in reducing levels of PP. The two MVMAs resulted in different
conclusions. MVMA with missing values imputed indicated that CDSSs had a significant
(less than small) effect on PP while MVMA with deleted missing values resulted in
nonsignificant effect of CDSSs on PP levels. This difference between the two MVMAs
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could be a result of extra information provided by imputing the missing values rather than
just deleting them. It can also be concluded that this result might change based on what
method was used--UVMA or MVMA (Jackson et al., 2011).
Overall Summary of the Findings
Looking back at the results of the simulation and the empirical meta-analyses
together, a number of conclusions can be drawn. First, the between-study correlation
appeared to have no effect on MVMA results. However, further investigation is need
since including the between-study correlation should have some effect on the outcome
estimates. Based on that null finding, the differences between the UVMAs and the
MVMAs estimates were a result of the other factors (sample size, percent of
missingness). Second, the simulation study and the meta-analyses of CDSSs showed that
MVMAs could give different conclusions compared to UVMAs as they include more
studies and more information about the outcomes. Third, it is important to state that effect
sizes did not differ to any interpretable extent across all of the analyses conducted, but
standard errors differed between UVMA and MVMA. As was found and as was expected,
standard errors decreased as sample size increased, and so, standard errors decreased with
no missing data and increased with a higher proportion of missing data. Fourth, CDSSs
showed a small effect overall on the dependent measures combined. Finally, based on the
findings taken together, MVMA is considered more precise since standard errors were
smaller.
Limitations of the Study
This study had limitations on two parts (simulation study and the empirical study
of CDSSs). In the simulation study, two outcomes were considered in order to make the
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process easier to explain. However, if three outcomes were included, the comparisons of
the findings of the simulation and the empirical meta-analyses of CDSSs would have
more strength and extend the logical conclusions. Another limitation was when missing
values were generated. In the simulation, the missing values were only placed on the
second outcome (ES = 0.5). The reason behind that was to see if the missingness would
only affect ES = 0.5 estimates or it would also affect ES = 0.7 estimates. However,
another possibility would be to assign missing values to all outcomes since it is usually
the case in real meta-analysis data. A final limitation is related to individual patient data.
In the simulation, it would be more accurate if individual patient level data were
generated and then meta-analyses were calculated.
Several limitations were also present in UVMAs and MVMAs for the CDSSs. In
the study search procedure, not all studies that were evaluating CDSSs on diabetes care
management were accessible. In studying the effect of CDSSs, there was no focus on a
specific type of CDSS. CDSSs differ in their effect according to their type and
mechanism. As a result, the effect sizes of the studies were varying and inconsistent and
hence heterogeneity was significant in most of the conducted meta-analyses.
Nevertheless, limiting the interest to only one type of CDSSs would severely decrease the
number of the studies included in a meta-analysis.
A critical issue that is more likely than not to be present in every MVMA is the
lack of reporting of the information needed for the analysis. In MVMA of CDSSs, no
within-study correlation was reported in the included studies. As a result, the researcher
computed the correlation between the three outcomes based on the literature. This
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correlation was then used to impute the covariances in order to run the analysis. Having
the actual correlations would result in more accurate findings.
Another common issue in MVMA is missing values. Two MVMAs were
performed—one with missing data deleted and one with missing data imputed. Deleting
the missing values was an option to get “rma.mv” to run since it does not deal with
missingingness. The other option was by imputing the missing values using multiple
imputation (MICE). This method assumes that missing values are missing at random
which is not always the case. If the possibility of being ignored directly relates with the
value of the data, then it is defined as missing not at random. For instance, some studies
might report the variances because they are large. Also, smaller studies, are more likely
ignore reporting variances compared to larger studies (Idris, 2011). Using multiple
imputations increased the standard errors of effect size estimates as can be seen in Table
34 (Jakobsen et al., 2017). Imputing the missing effect sizes of CDSSs relied on the
available information of the other studies. This could be misleading since not all studies
have the same CDSS and not all CDSSs had the same effect.
Recommendations for Future Study
Several recommendations for future study that could help in furthering our
understanding of UVMA and MVMA are provided below.
1- The simulation could be conducted with three or more outcomes with missing
values placed randomly on all of them. This could give more insight into
conclusions when comparing a simulation with an empirical MVMA.
2- The number of the replications used in the simulation was 1000 replications.
Fewer replications could yield much the same accuracy and could be
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examined with respect to making the simulation easier to conduct. It is
recommended that future study examine use of 100 and 500 replications.
3- Considering the individual patient data when generating meta-analysis data
would allow the researcher to adequately calculate within-study and betweenstudy correlations.
4- Even though the consideration of the between-study correlation showed had
no effect on the effect size estimates, further investigation using different
effect sizes (very small or very large) might reveal some effect of the
correlation on the effect size estimates.
5- Meta-analysis could be conducted to evaluate one type of CDSS or at least
evaluate CDSSs sharing the same characteristics.
6- Due to the intent of this study, the effects of moderator variables were not
examined. Conducting this study with the consideration of moderators that
might affect the variation between the selected studies could be beneficial.
7- Researchers are encouraged to report vital information that could help in
doing a complete meta-analysis and avoid deleting or imputing values that are
missing. Alternatively, researchers could provide both solutions—with and
without imputed values.
8- R Packages that are designed to conduct MVMA need to be developed to
handle missing values and efficiently perform publication bias evaluation.
As an assistant lecturer at the University of Benghazi, faculty of public
health/department of health informatics, one of my interests was to see how CDSSs
would help diabetes physicians and patients in managing diabetes. After I took a meta107

analysis course, I thought that conducting meta-analysis would give a more precise
conclusion about how effective CDSSs are. Since evaluating CDSSs was based on three
outcomes (LDL, HbA1c, and BP), MVMA was the only efficient way to do such a metaanalysis. However, the use of the MVMA was limited in the literature and the effect of
some factors on MVMA estimates were unknown. Therefore, and after consulting my
professors, I decided to conduct simulation study first to and then conduct the study of
CDSSs. This study was important to the field as relatively little is known about factors
influencing MVMA and to me personally because it would help decision makers and
health officials in Libya in making decisions on whether or not CDSSs would help
improving health care.
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Appendix B: IRB Determination Letter

March 15, 2021
Abdelfattah Elbarsha
Research Methods and Information Science
Morgridge College of Education
University of Denver
RE: Determination of Proposed Project
Project Title: Evaluation of the Effect of the Clinical Decision Support Systems on Diabetes
Management: A Multivariate Meta-Analysis Comparison with Univariate Meta-Analysis
Dear Abdelfattah,
Thank you for submitting the IRB Determination Form, to the University of Denver Institutional
Review Board for evaluation to determine if the above-referenced project qualifies as human
subject research. Based on the information provided, it has been determined that the
proposed project does not require IRB review. This determination is based on whether this
proposed project is research with human subjects defined by the federal regulations.
The IRB Determination Form was evaluated and it was assessed that the proposed
metaanalysis project does not qualify as human subjects research. The planned meta-analysis
of publicly available data from published articles does not meet the regulatory definition of
research with human subjects.
The Regulatory Definition of Research and Human Subject
Federal research regulations define research as “a systematic investigation, including research
development, testing, and evaluation, designed to develop or contribute to generalizable
knowledge.”
During the review of this proposed project, it was noted that the primary intent is to determine
how and when estimated produced by multivariate meta-analysis would be different and more
statistically precise compared to estimates produced by separate univariate meta-analyses, and
to examine the effects of clinical decision support systems on the quality of diabetes care
management. This study will analyze de-identified and publicly available datasets found from
published articles. This project is designed to develop generalizable knowledge, and therefore
this project does qualify as research.
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Per the regulations, Human subject means a living individual about whom an investigator
(whether professional or student) conducting research obtains 1) data through intervention or
interaction with the individual, or 2) identifiable private information. This project does not
involve interaction with living individuals and will utilize de-identified secondary data only,
therefore it does not qualify as involving human subjects.
In order for a project to require IRB review, the proposed research must qualify under both
definitions of being research and involving human subjects. This research project does fulfill
the regulatory definition of research but does NOT involve human subjects per the federal
regulation definition.
My evaluation, based only on the information provided, determined that the proposed project
does not require IRB review.
If you have questions regarding this determination or believe that this proposed project does
qualify as human subject research, please feel free to contact me directly at 303-871-4051 or
via e-mail at: Ashleigh.Ruehrdanz@du.edu.
Sincerely,

Ashleigh Ruehrdanz
Research Compliance Monitor
Office of Research and Sponsored Programs
University of Denver

131

